IL-23 induces spondyloarthropathy by acting on ROR-Î³ cells

Nature Medicine

18, 1069-1076

DOI: 10.1038/nm.2817

Citation Report

#	Article	IF	Citations
1	Emerging concepts in ankylosing spondylitis. International Journal of Clinical Rheumatology, 2012, 7, 515-526.	0.3	0
2	Pathophysiology of New Bone Formation and Ankylosis in Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 555-567.	0.8	79
3	IL-23 specifics in spondyloarthritis. Nature Reviews Rheumatology, 2012, 8, 439-439.	3.5	1
4	Dietary influences on intestinal immunity. Nature Reviews Immunology, 2012, 12, 696-708.	10.6	131
5	Pathophysiology and Role of the Gastrointestinal System in Spondyloarthritides. Rheumatic Disease Clinics of North America, 2012, 38, 569-582.	0.8	30
6	IL-23 tees off enthesitis. Nature Reviews Immunology, 2012, 12, 553-553.	10.6	2
7	Primed for inflammation: enthesis-resident T cells. Nature Medicine, 2012, 18, 1018-1019.	15.2	87
8	The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis. Biologics in Therapy, 2013, 3, 61-81.	1.8	0
9	How Cytokine Networks Fuel Inflammation: Interleukin-17 and a tale of two autoimmune diseases. Nature Medicine, 2013, 19, 824-825.	15.2	84
10	Treatment Challenges in Axial Spondylarthritis and Future Directions. Current Rheumatology Reports, 2013, 15, 356.	2.1	5
11	Osteoimmunology and Bone Homeostasis: Relevance to Spondyloarthritis. Current Rheumatology Reports, 2013, 15, 342.	2.1	22
12	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet, The, 2013, 382, 780-789.	6.3	688
13	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2013, 382, 1705-1713.	6.3	518
14	Brief Report: The IL23R Nonsynonymous Polymorphism rs11209026 Is Associated With Radiographic Sacroiliitis in Spondyloarthritis. Arthritis and Rheumatism, 2013, 65, 2655-2660.	6.7	17
15	Th17 Cells in Autoimmune Inflammation and Demyelination in the Central Nervous System. , 2013, , 1-25.		1
16	Polymorphism of HLA-B27: 105 Subtypes Currently Known. Current Rheumatology Reports, 2013, 15, 362.	2.1	81
17	Th17 cells and IL-17 Aâ€"Focus on immunopathogenesis and immunotherapeutics. Seminars in Arthritis and Rheumatism, 2013, 43, 158-170.	1.6	125
18	Update on Juvenile Spondyloarthritis. Rheumatic Disease Clinics of North America, 2013, 39, 767-788.	0.8	40

#	Article	IF	Citations
19	Parallel evolution of OA phenotypes and therapies. Nature Reviews Rheumatology, 2013, 9, 68-70.	3.5	45
20	HLAâ€“B27 Alters the Response to Tumor Necrosis Factor Î± and Promotes Osteoclastogenesis in Bone Marrow Monocytes From HLAâ€“B27â€“Transgenic Rats. Arthritis and Rheumatism, 2013, 65, 2123-2131.	6.7	29
21	Mechanistic Insights from Animal Models of Psoriasis and Psoriatic Arthritis. Current Rheumatology Reports, 2013, 15, 377.	2.1	14
22	Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Research and Therapy, 2013, 15, R136.	1.6	212
23	Pathogenesis of hyperostosis: A key role for mesenchymatous cells?. Joint Bone Spine, 2013, 80, 592-596.	0.8	18
24	What can rheumatologists learn from translational cancer therapy?. Arthritis Research and Therapy, 2013, 15, 114.	1.6	8
25	Microbes, the gut and ankylosing spondylitis. Arthritis Research and Therapy, 2013, 15, 214.	1.6	71
26	Psoriatic arthritis: recent progress in pathophysiology and drug development. Arthritis Research and Therapy, 2013, 15, 224.	1.6	22
27	Advances in catheter-ablation treatment of AF. Nature Reviews Cardiology, 2013, 10, 63-64.	6.1	7
28	The resolution of inflammation. Nature Reviews Immunology, 2013, 13, 59-66.	10.6	454
29	Th17 cell development: from the cradle to the grave. Immunological Reviews, 2013, 252, 78-88.	2.8	180
30	Mucosal immunity in liver autoimmunity: A comprehensive review. Journal of Autoimmunity, 2013, 46, 97-111.	3.0	110
31	Enthesitis in psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2013, 43, 325-334.	1.6	66
32	17 and 23: prime numbers for ankylosing spondylitis?. Lancet, The, 2013, 382, 1682-1683.	6.3	3
33	Autophagy and inflammatory diseases. Immunology and Cell Biology, 2013, 91, 250-258.	1.0	111
34	The ups and downs of bone in health and rheumatic disease. Nature Reviews Rheumatology, 2013, 9, 67-68.	3.5	7
35	In Situ Analysis of Interleukinâ€“23â€“ and Interleukinâ€“12â€“Positive Cells in the Spine of Patients With Ankylosing Spondylitis. Arthritis and Rheumatism, 2013, 65, 1522-1529.	6.7	121
36	<scp>IL</scp>â€22, not simply a Th17 cytokine. Immunological Reviews, 2013, 252, 116-132.	2.8	391

#	Article	IF	Citations
37	Advances in the Genetics of Spondyloarthritis and Clinical Implications. Current Rheumatology Reports, 2013, 15, 347.	2.1	11
38	Psoriatic arthritis: current therapy and future directions. Expert Opinion on Pharmacotherapy, 2013, 14, 1755-1764.	0.9	9
39	Interleukin-23: a promising therapeutic target in seronegative spondyloarthropathy. Current Opinion in Pharmacology, 2013, 13, 445-448.	1.7	11
40	IL-17 in the Rheumatologistâ€™s Line of Sight. BioMed Research International, 2013, 2013, 1-18.	0.9	24
41	Treatment of spondyloarthropathy. Current Opinion in Rheumatology, 2013, 25, 455-459.	2.0	16
42	Autoreactive Th1 Cells Activate Monocytes To Support Regional Th17 Responses in Inflammatory Arthritis. Journal of Immunology, 2013, 190, 3134-3141.	0.4	10
43	The role of natural killer cells, gamma delta T-cells and other innate immune cells in spondyloarthritis. Current Opinion in Rheumatology, 2013, 25, 434-439.	2.0	16
44	Dendritic cells and regulatory T cells in spondyloarthritis. Current Opinion in Rheumatology, 2013, 25, 440-447.	2.0	6
45	Spondyloarthropathy: frontier for molecular targets?. Expert Review of Clinical Immunology, 2013, 9, 289-291.	1.3	1
46	How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy. Nature Medicine, 2013, 19, 822-824.	15.2	341
48	Combinatorial Control of Th17 and Th1 Cell Functions by Genetic Variations in Genes Associated With the Interleukinâ€23 Signaling Pathway in Spondyloarthritis. Arthritis and Rheumatism, 2013, 65, 1510-1521.	6.7	51
49	Immunopathogenesis of ankylosing spondylitis. International Journal of Clinical Rheumatology, 2013, 8, 265-274.	0.3	22
50	Advances in pathogenesis through animal models and imaging. Nature Reviews Rheumatology, 2013, 9, 72-74.	3.5	5
51	Epidemiology, genetics and management of psoriatic arthritis 2013: focus on developments of who develops the disease, its clinical features, and emerging treatment options. Psoriasis: Targets and Therapy, 2013, , 11.	1.2	1
52	Consumption of Lactobacillus casei Fermented Milk Prevents Salmonella Reactive Arthritis by Modulating IL-23/IL-17 Expression. PLoS ONE, 2013, 8, e82588.	1.1	33
53	New aspects of spondyloarthritis pathogenesis. Part III â€“ arthritis, pathological bone remodeling. Reumatologia, 2014, 4, 247-254.	0.5	2
54	Vitamin D and spondyloarthritis. Expert Review of Clinical Immunology, 2014, 10, 1581-1589.	1.3	9
55	Tissue specific CD4+ T cell priming determines the requirement for interleukin-23 in experimental arthritis. Arthritis Research and Therapy, 2014, 16, 440.	1.6	4

#	Article	IF	Citations
56	Current Concepts in Psoriatic Arthritis: Pathogenesis and Management. Acta Dermato-Venereologica, 2014, 94, 627-634.	0.6	58
57	Bone Formation in Psoriatic Arthritis: A Report from the GRAPPA 2013 Annual Meeting. Journal of Rheumatology, 2014, 41, 1218-1219.	1.0	14
58	Autoimmunity: Break-through in the diagnosis and treatment of immune-mediated inflammatory diseases. Immunology Letters, 2014, 162, 150-162.	1.1	4
59	IL-23 expression and activation of autophagy in synovium and PBMCs of HLA-B27 positive patients with ankylosing spondylitis. Response to: â€˜Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammationâ€™ by Cicciaet al. Annals of the Rheumatic Diseases, 2014, 73, e68-e68.	0.5	22
60	How do <scp>T</scp>h17 cells mediate autoimmune inflammation in the central nervous system?. Clinical and Experimental Neuroimmunology, 2014, 5, 120-131.	0.5	1
61	Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Annals of the Rheumatic Diseases, 2014, 73, 437-445.	0.5	334
62	ZAPâ€70 Genotype Disrupts the Relationship Between Microbiota and Host, Leading to Spondyloarthritis and Ileitis in SKG Mice. Arthritis and Rheumatology, 2014, 66, 2780-2792.	2.9	148
63	The IL-20 subfamily of cytokines â€" from host defence to tissue homeostasis. Nature Reviews Immunology, 2014, 14, 783-795.	10.6	287
64	Editorial: Emerging Evidence for Critical Involvement of the Interleukinâ€17 Pathway in Both Psoriasis and Psoriatic Arthritis. Arthritis and Rheumatology, 2014, 66, 1077-1080.	2.9	25
65	Bone formation in axial spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 765-777.	1.4	45
66	The role of the gut and microbes in the pathogenesis of spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 687-702.	1.4	87
67	Treatment of spondyloarthritis beyond TNF-alpha blockade. Best Practice and Research in Clinical Rheumatology, 2014, 28, 819-827.	1.4	25
68	The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it. Best Practice and Research in Clinical Rheumatology, 2014, 28, 703-710.	1.4	63
69	Large vessel vasculitis and spondyloarthritis: coincidence or associated diseases?. Scandinavian Journal of Rheumatology, 2014, 43, 246-248.	0.6	26
70	The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Current Opinion in Rheumatology, 2014, 26, 361-370.	2.0	78
71	The effect of tumor necrosis factor-blockade on new bone formation in ankylosing spondylitis. Current Opinion in Rheumatology, 2014, 26, 389-394.	2.0	4
72	Inflammatory Bone Spur Formation in Psoriatic Arthritis Is Different From Bone Spur Formation in Hand Osteoarthritis. Arthritis and Rheumatology, 2014, 66, 2968-2975.	2.9	41
73	T cell subsets and their role in the pathogenesis of rheumatic disease. Current Opinion in Rheumatology, 2014, 26, 204-210.	2.0	85

#	Article	IF	Citations
74	â€˜Bamboo spineâ€™, a thing of the past?. International Journal of Rheumatic Diseases, 2014, 17, 127-130.	0.9	1
75	Inflammatory pathways in spondyloarthritis. Molecular Immunology, 2014, 57, 28-37.	1.0	113
76	Genetics of ankylosing spondylitis. Molecular Immunology, 2014, 57, 2-11.	1.0	109
77	HLA-B27 misfolding and ankylosing spondylitis. Molecular Immunology, 2014, 57, 44-51.	1.0	184
79	The Interleukin-17 Pathway in Psoriasis and Psoriatic Arthritis: Disease Pathogenesis and Possibilities of Treatment. Current Rheumatology Reports, 2014, 16, 414.	2.1	36
80	Impact of Inflammation on the Osteoblast in Rheumatic Diseases. Current Osteoporosis Reports, 2014, 12, 9-16.	1.5	110
81	IL-21 induces IL-22 production in CD4+ T cells. Nature Communications, 2014, 5, 3753.	5.8	134
82	Specific targeting of interleukin-23p19 as effective treatment for psoriasis. Journal of the American Academy of Dermatology, 2014, 70, 555-561.	0.6	60
83	Review: The Interleukinâ€23/Interleukinâ€17 Axis in Spondyloarthritis Pathogenesis: Th17 and Beyond. Arthritis and Rheumatology, 2014, 66, 231-241.	2.9	192
84	Interleukinâ€23 Mediates the Intestinal Response to Microbial Î²â€1,3â€Glucan and the Development of Spondyloarthritis Pathology in SKG Mice. Arthritis and Rheumatology, 2014, 66, 1755-1767.	2.9	183
85	Clinicianâ€™s Manual on Axial Spondyloarthritis. , 2014, , .		3
86	Innate lymphoid cells: New paradigm in immunology of inflammation. Immunology Letters, 2014, 157, 23-37.	1.1	46
87	The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies. Autoimmunity Reviews, 2014, 13, 64-69.	2.5	49
89	Cytokine Frontiers. , 2014, , .		25
90	Halofuginone-Induced Amino Acid Starvation Regulates Stat3-Dependent Th17 Effector Function and Reduces Established Autoimmune Inflammation. Journal of Immunology, 2014, 192, 2167-2176.	0.4	26
91	Therapeutic opportunities of the IL-22â€“IL-22R1 system. Nature Reviews Drug Discovery, 2014, 13, 21-38.	21.5	464
92	The critical role of interleukin-23 in spondyloarthropathy. Molecular Immunology, 2014, 57, 38-43.	1.0	58
93	Judicious Use of Biologicals in Juvenile Idiopathic Arthritis. Current Rheumatology Reports, 2014, 16, 454.	2.1	16

#	Article	IF	Citations
94	Reverse Interferon Signature Is Characteristic of Antigenâ€Presenting Cells in Human and Rat Spondyloarthritis. Arthritis and Rheumatology, 2014, 66, 841-851.	2.9	51
95	Spondyloarthritis: from unifying concepts to improved treatment. Rheumatology, 2014, 53, 1547-1559.	0.9	33
96	High frequency of reactive arthritis in adults afterYersinia pseudotuberculosisO:1 outbreak caused by contaminated grated carrots: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 1793-1796.	0.5	25
97	The IL-23â€“IL-17 immune axis: from mechanisms to therapeutic testing. Nature Reviews Immunology, 2014, 14, 585-600.	10.6	1,267
98	Psoriatic Enthesitis: An Update from the GRAPPA 2013 Annual Meeting. Journal of Rheumatology, 2014, 41, 1220-1223.	1.0	6
99	Oral-resident natural Th17 cells and Î³Î´ T cells control opportunistic Candida albicans infections. Journal of Experimental Medicine, 2014, 211, 2075-2084.	4.2	217
100	Recognition of Preclinical and Early Disease in Axial Spondyloarthritis. Rheumatic Disease Clinics of North America, 2014, 40, 685-697.	0.8	10
102	Suppression of human and mouse Th17 differentiation and autoimmunity by an endogenous Interleukin 23 receptor cytokine-binding homology region. International Journal of Biochemistry and Cell Biology, 2014, 55, 304-310.	1.2	15
103	Investigational drugs for treating psoriatic arthritis. Expert Opinion on Investigational Drugs, 2014, 23, 1001-1016.	1.9	7
106	Spondyloarthritis: may the force be with you?. Annals of the Rheumatic Diseases, 2014, 73, 321-323.	0.5	20
107	Cellular and molecular mechanisms of bone damage and repair in inflammatory arthritis. Drug Discovery Today, 2014, 19, 1178-1185.	3.2	6
108	Editorial: Animal Models of Spondyloarthritis: Do They Faithfully Mirror Human Disease?. Arthritis and Rheumatology, 2014, 66, 1689-1692.	2.9	19
109	Biomarkers in Psoriatic Arthritis: Recent Progress. Current Rheumatology Reports, 2014, 16, 453.	2.1	21
110	Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?. Annals of the Rheumatic Diseases, 2014, 73, 951-953.	0.5	6
111	Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Annals of the Rheumatic Diseases, 2014, 73, 1000-1006.	0.5	255
112	Unanswered questions in the management of axial spondyloarthritis: an opinion piece. Clinical Rheumatology, 2014, 33, 1359-1365.	1.0	1
114	Autoimmune and autoinflammatory mechanisms in uveitis. Seminars in Immunopathology, 2014, 36, 581-594.	2.8	120
115	Wnt signaling in ankylosing spondylitis. Clinical Rheumatology, 2014, 33, 759-762.	1.0	45

#	Article	IF	Citations
116	Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells. Mucosal Immunology, 2014, 7, 842-856.	2.7	127
117	Diagnosing and treating psoriatic arthritis: an update. British Journal of Dermatology, 2014, 170, 772-786.	1.4	28
118	Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Annals of the Rheumatic Diseases, 2014, 73, 817-823.	0.5	236
119	Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Annals of the Rheumatic Diseases, 2014, 73, 1566-1574.	0.5	145
120	Peripheral joint inflammation in early onset spondyloarthritis is not specifically related to enthesitis. Annals of the Rheumatic Diseases, 2014, 73, 735-740.	0.5	31
121	Immunopathologie actuelle. Revue Du Rhumatisme Monographies, 2014, 81, 235-239.	0.0	1
122	Importance des cellules CD103+ dans la pathogÃ©nie des spondyloarthrites. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 460-465.	0.0	0
123	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2014, 73, 6-16.	0.5	397
124	Axial spondyloarthritis. Medicine, 2014, 42, 251-256.	0.2	4
125	Lymphotoxin organizes contributions to host defense and metabolic illness from innate lymphoid cells. Cytokine and Growth Factor Reviews, 2014, 25, 227-233.	3.2	14
126	Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis. New England Journal of Medicine, 2014, 370, 2295-2306.	13.9	350
127	Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clinical Immunology, 2014, 154, 1-12.	1.4	110
128	Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: A cross-sectional study. Seminars in Arthritis and Rheumatism, 2014, 44, 309-313.	1.6	18
129	The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis. The Application of Clinical Genetics, 2014, 7, 105.	1.4	86
130	Advances in treating psoriasis. F1000prime Reports, 2014, 6, 4.	5.9	58
131	Advances in managing ankylosing spondylitis. F1000prime Reports, 2014, 6, 78.	5.9	22
132	New immune cells in spondyloarthritis: Key players or innocent bystanders?. Best Practice and Research in Clinical Rheumatology, 2015, 29, 706-714.	1.4	17
133	Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Research and Therapy, 2015, 17, 115.	1.6	147

#	Article	IF	Citations
134	Relationship of CD146 expression to secretion of interleukin (IL)-17, IL-22 and interferon-Î³ by CD4+ T cells in patients with inflammatory arthritis. Clinical and Experimental Immunology, 2015, 179, 378-391.	1.1	17
135	Axial spondyloarthritis. Nature Reviews Disease Primers, 2015, 1, 15013.	18.1	135
136	OsteoRheumatology: a new discipline?. RMD Open, 2015, 1, e000083.	1.8	9
137	Lâ€™intestin des spondyloarthrites. Revue Du Rhumatisme (Edition Francaise), 2015, 82, A19-A22.	0.0	1
138	Editorial: HLAâ€“B27: The Story Continues to Unfold. Arthritis and Rheumatology, 2016, 68, 1057-1059.	2.9	9
139	Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and SjÃ¶gren syndrome. Report of two cases and review of literature.. Journal of Dermatological Case Reports, 2015, 9, 71-5.	1.1	8
140	A Prospective Study on Inflammatory Cytokines and Bone Metabolism Mediators in Patients Affected by Rheumatoid and Psoriatic Arthritis treated with Adalimumab. Journal of Arthritis, 2015, 04, .	0.3	1
141	Pathogenesis of Ankylosing Spondylitis. Journal of Rheumatic Diseases, 2015, 22, 61.	0.4	3
142	Optimal management of dactylitis in patients with psoriatic arthritis. Open Access Rheumatology: Research and Reviews, 2015, 7, 55.	0.8	11
143	HLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic Rats. PLoS ONE, 2015, 10, e0130811.	1.1	9
144	Enthesopathies and enthesitis. Part 1. Etiopathogenesis. , 2015, 15, 72-84.		33
145	Immune cell profiling to guide therapeutic decisions in rheumatic diseases. Nature Reviews Rheumatology, 2015, 11, 541-551.	3.5	62
146	Spondyloarthropathy: interleukin 23 and disease modification. Lancet, The, 2015, 385, 2017-2018.	6.3	21
147	Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scandinavian Journal of Rheumatology, 2015, 44, 118-124.	0.6	54
148	Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond. Seminars in Immunopathology, 2015, 37, 335-347.	2.8	37
149	Decreased Bacterial Diversity Characterizes the Altered Gut Microbiota in Patients With Psoriatic Arthritis, Resembling Dysbiosis in Inflammatory Bowel Disease. Arthritis and Rheumatology, 2015, 67, 128-139.	2.9	602
150	Systemic Manifestations of Mucosal Diseases. , 2015, , 1749-1759.		0
151	SnapShot: Osteoimmunology. Cell Metabolism, 2015, 21, 502-502.e1.	7.2	20

#	Article	IF	Citations
152	Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. Journal of Clinical Investigation, 2015, 125, 2211-2219.	3.9	204
153	Inflammatory signaling induced bone loss. Bone, 2015, 80, 143-149.	1.4	29
154	Dual RAAS blockade for kidney failure: hope for the future. Lancet, The, 2015, 385, 2018-2020.	6.3	2
155	Making the next steps in psoriatic arthritis management: current status and future directions. Therapeutic Advances in Musculoskeletal Disease, 2015, 7, 173-186.	1.2	9
156	Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. Expert Opinion on Biological Therapy, 2015, 15, 1727-1737.	1.4	29
157	Limited ultrasound protocol of the Achilles enthesis. Rheumatology, 2015, 54, 1539-1540.	0.9	1
158	Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions. Immunity, 2015, 43, 1040-1051.	6.6	425
159	Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. New England Journal of Medicine, 2015, 373, 2534-2548.	13.9	803
160	Therapeutic targets in psoriatic arthritis. International Journal of Clinical Rheumatology, 2015, 10, 489-499.	0.3	1
161	In vivo pre-activation of monocytes in patients with axial spondyloarthritis. Arthritis Research and Therapy, 2015, 17, 179.	1.6	30
162	Inflammation, bone loss and fracture risk in spondyloarthritis: FigureÂ1. RMD Open, 2015, 1, e000052.	1.8	51
164	The IL-23/Th 17 pathway in spondyloarthritis: The Royal Road?. Joint Bone Spine, 2015, 82, 1-4.	0.8	37
165	Infection and Spondyloarthropathies. , 2015, , 745-757.		0
166	Spondyloarthritis and the Microbiome: New Insights From an Ancient Hypothesis. Current Rheumatology Reports, 2015, 17, 10.	2.1	16
167	Essential role for CD103+ cells in the pathogenesis of spondyloarthritides. Joint Bone Spine, 2015, 82, 8-12.	0.8	16
168	Autoimmune Valvular Carditis. Current Allergy and Asthma Reports, 2015, 15, 491.	2.4	13
169	Two-faced immunologyâ€"from osteogenesis to bone resorption. Nature Reviews Rheumatology, 2015, 11, 74-76.	3.5	48
170	Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opinion on Emerging Drugs, 2015, 20, 1-14.	1.0	40

#	Article	IF	Citations
172	Observations on Chlamydia trachomatis and other microbes in reactive arthritis. International Journal of STD and AIDS, 2015, 26, 139-144.	0.5	14
173	Resident memory T cells in human health and disease. Science Translational Medicine, 2015, 7, 269rv1.	5.8	347
174	Spreading spondyloarthritis: are ILCs cytokine shuttles from base camp gut?. Annals of the Rheumatic Diseases, 2015, 74, 1633-1635.	0.5	12
175	Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis. Current Rheumatology Reports, 2015, 17, 55.	2.1	42
176	Pathogenesis of BehÃ§etâ€™s disease: autoinflammatory features and beyond. Seminars in Immunopathology, 2015, 37, 413-418.	2.8	107
177	The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nature Medicine, 2015, 21, 688-697.	15.2	455
178	Complications rachidiennes de la spondyloarthrite ankylosante. Revue Du Rhumatisme Monographies, 2015, 82, 42-47.	0.0	0
179	Programmed Cell Death 1 and Helios Distinguish TCR-Î±Î²+ Double-Negative (CD4âˆ’CD8âˆ’) T Cells That Derive from Self-Reactive CD8 T Cells. Journal of Immunology, 2015, 194, 4207-4214.	0.4	53
180	The IL-23â€“IL-17 axis in inflammatory arthritis. Nature Reviews Rheumatology, 2015, 11, 415-429.	3.5	338
181	Genetic architectures of seropositive and seronegative rheumatic diseases. Nature Reviews Rheumatology, 2015, 11, 401-414.	3.5	39
182	IL-23 Responsive Innate-Like T Cells in Spondyloarthritis: the Less Frequent They Are, the More Vital They Appear. Current Rheumatology Reports, 2015, 17, 30.	2.1	23
183	IL12/IL23 Inhibition in the Treatment of Psoriatic Arthritis. Current Treatment Options in Rheumatology, 2015, 1, 197-209.	0.6	3
184	IL-17 and Its Receptor System: a New Target for Psoriatic Arthritis. Current Treatment Options in Rheumatology, 2015, 1, 210-220.	0.6	2
185	IL-17 Inhibition in Axial Spondyloarthritis. Current Treatment Options in Rheumatology, 2015, 1, 221-230.	0.6	2
186	Blocking Interleukin-12 and Interleukin-23 in the Treatment of Axial Spondyloarthritis. Current Treatment Options in Rheumatology, 2015, 1, 231-238.	0.6	0
187	Enthesitis as a component of dactylitis in psoriatic juvenile idiopathic arthritis: histology of an established clinical entity. Pediatric Rheumatology, 2015, 13, 7.	0.9	24
188	CCL20andIL22Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis. JAMA Dermatology, 2015, 151, 837.	2.0	38
189	Use of brodalumab for the treatment of psoriasis and psoriatic arthritis. Immunotherapy, 2015, 7, 323-333.	1.0	10

#	Article	IF	Citations
190	What makes psoriatic and rheumatoid arthritis so different?. RMD Open, 2015, 1, e000025-e000025.	1.8	75
191	Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2015, 74, 1739-1747.	0.5	236
192	DCIR Maintains Bone Homeostasis by Regulating IFN-Î³ Production in T Cells. Journal of Immunology, 2015, 194, 5681-5691.	0.4	34
193	Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clinical Rheumatology, 2015, 34, 1019-1023.	1.0	57
194	The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases. Current Opinion in Rheumatology, 2015, 27, 71-75.	2.0	22
195	What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?. Current Opinion in Rheumatology, 2015, 27, 91-98.	2.0	38
196	Integrating the pathogenesis of spondyloarthritis. Current Opinion in Rheumatology, 2015, 27, 189-196.	2.0	24
197	Targeting extra-articular manifestations in PsA. Current Opinion in Rheumatology, 2015, 27, 111-117.	2.0	31
198	Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Current Opinion in Rheumatology, 2015, 27, 127-133.	2.0	151
199	HLA-B27. Annual Review of Immunology, 2015, 33, 29-48.	9.5	189
200	Biologic Therapy for Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 723-738.	0.8	52
201	Ten years after: rheumatology research from bench to bedside. Nature Reviews Rheumatology, 2015, 11, 623-624.	3.5	2
202	Gdf5 progenitors give rise to fibrocartilage cells that mineralize via hedgehog signaling to form the zonal enthesis. Developmental Biology, 2015, 405, 96-107.	0.9	96
203	Inflammation activation and resolution in human tendon disease. Science Translational Medicine, 2015, 7, 311ra173.	5.8	192
204	'MHC-I-opathy'â€"unified concept for spondyloarthritis and BehÃ§et disease. Nature Reviews Rheumatology, 2015, 11, 731-740.	3.5	183
205	Review: Animal Models as a Tool to Dissect Pivotal Pathways Driving Spondyloarthritis. Arthritis and Rheumatology, 2015, 67, 2813-2827.	2.9	44
206	Macrophages derived from THP-1 promote the osteogenic differentiation of mesenchymal stem cells through the IL-23/IL-23R/Î²-catenin pathway. Experimental Cell Research, 2015, 339, 81-89.	1.2	23
207	Role of stem cells in spondyloarthritis: Pathogenesis, treatment and complications. Human Immunology, 2015, 76, 781-788.	1.2	7

#	Article	IF	Citations
208	Role of genetics in infection-associated arthritis. Best Practice and Research in Clinical Rheumatology, 2015, 29, 213-225.	1.4	5
209	Biologics in spondyloarthritis: TNFÎ± inhibitors and other agents. Immunotherapy, 2015, 7, 669-681.	1.0	14
210	Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs, 2015, 7, 778-791.	2.6	92
211	Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 405-414.	1.0	26
212	Nociceptive Sensory Fibers Drive Interleukin-23 Production from CD301b+ Dermal Dendritic Cells and Drive Protective Cutaneous Immunity. Immunity, 2015, 43, 515-526.	6.6	306
213	Etiology and Pathogenesis of Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 643-663.	0.8	58
214	Old and new treatment targets in axial spondyloarthritis. RMD Open, 2015, 1, e000054.	1.8	13
215	Enthesitis: The clue to the pathogenesis of spondyloarthritis?. Joint Bone Spine, 2015, 82, 402-405.	0.8	10
216	The role of secukinumab in the treatment of ankylosing spondylitis. Immunotherapy, 2015, 7, 1241-1247.	1.0	3
217	An Integrative Approach to Biomarker Development in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2015, 93, 43-47.	2.2	1
218	Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis. Internal Medicine Journal, 2015, 45, 127-133.	0.5	5
219	Update on Ankylosing Spondylitis: Current Concepts in Pathogenesis. Current Allergy and Asthma Reports, 2015, 15, 489.	2.4	177
220	Dynamics of syndesmophyte growth in AS as measured by quantitative CT: heterogeneity within and among vertebral disc spaces. Rheumatology, 2015, 54, 972-980.	0.9	7
221	IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1284-1292.	0.5	76
222	Psoriatic Arthritis for the Dermatologist. Dermatologic Clinics, 2015, 33, 127-148.	1.0	13
223	Psoriatic arthritis: current therapy and future approaches. Rheumatology, 2015, 54, 20-28.	0.9	56
224	Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology, 2015, 54, 29-38.	0.9	64
225	Psoriasis and Psoriatic Arthritis: Flip Sides of the Coin?. Acta Dermato-Venereologica, 2016, 96, 436-441.	0.6	18

#	Article	IF	Citations
226	The Role of the Immune System in the Local and Systemic Bone Loss of Inflammatory Arthritis. , 2016, , 241-256.		3
227	Secukinumab for ankylosing spondylitis and psoriatic arthritis. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1587-1592.	0.9	39
228	Mucosal-associated invariant T cells from induced pluripotent stem cells: A novel approach for modeling human diseases. World Journal of Stem Cells, 2016, 8, 158.	1.3	6
230	Interleukin 23 in IBD Pathogenesis. , 0, , .		3
231	Microtrauma. Current Opinion in Rheumatology, 2016, 28, 176-180.	2.0	38
232	The interaction between host genetics and the microbiome in the pathogenesis of spondyloarthropathies. Current Opinion in Rheumatology, 2016, 28, 405-412.	2.0	40
233	Targeting the interleukin-23/17 axis in axial spondyloarthritis. Current Opinion in Rheumatology, 2016, 28, 359-367.	2.0	44
234	Bone remodeling in psoriasis and psoriatic arthritis. Current Opinion in Rheumatology, 2016, 28, 66-75.	2.0	24
235	Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment. Arthritis and Rheumatology, 2016, 68, 312-322.	2.9	128
236	Increased Frequency of Th17 Cells in Children With Mycoplasma pneumoniae Pneumonia. Journal of Clinical Laboratory Analysis, 2016, 30, 1214-1219.	0.9	14
237	Subclinical gut inflammation in ankylosing spondylitis. Current Opinion in Rheumatology, 2016, 28, 89-96.	2.0	61
238	Interleukinâ€23â€“Dependent Î³/Î´ T Cells Produce Interleukinâ€17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice. Arthritis and Rheumatology, 2016, 68, 2476-2486.	2.9	170
239	Small molecule mediated inhibition of <scp>ROR</scp>Î³â€dependent gene expression and autoimmune disease pathology in vivo. Immunology, 2016, 147, 399-413.	2.0	45
240	MAIT cells: not just another brick in the wall. Annals of the Rheumatic Diseases, 2016, 75, 2057-2059.	0.5	16
241	Functional defects in CD4+ CD25high FoxP3+ regulatory cells in ankylosing spondylitis. Scientific Reports, 2016, 6, 37559.	1.6	39
242	Pharmacologic modulation of RORÎ³t translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis. Scientific Reports, 2016, 6, 37977.	1.6	62
243	Juvenile-Onset Spondyloarthritis. Handbook of Systemic Autoimmune Diseases, 2016, 11, 31-52.	0.1	2
244	Inhibition of RORÎ³T Skews TCRÎ± Gene Rearrangement and Limits T Cell Repertoire Diversity. Cell Reports, 2016, 17, 3206-3218.	2.9	51

#	Article	IF	Citations
245	Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology, 2017, 56, kew384.	0.9	74
246	Autoinflammation and HLA-B27: Beyond Antigen Presentation. Ocular Immunology and Inflammation, 2016, 24, 460-469.	1.0	14
247	Secukinumab: A New Treatment Option for Psoriatic Arthritis. Rheumatology and Therapy, 2016, 3, 5-29.	1.1	47
248	Killer immunoglobulin receptor genes in spondyloarthritis. Current Opinion in Rheumatology, 2016, 28, 368-375.	2.0	7
249	IL-23/IL-17 axis in spondyloarthritis-bench to bedside. Clinical Rheumatology, 2016, 35, 1437-1441.	1.0	36
250	The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis. Current Rheumatology Reports, 2016, 18, 33.	2.1	7
251	The gut in spondyloarthritis. Joint Bone Spine, 2016, 83, 401-405.	0.8	30
253	Functional Genomics and Its Bench-to-Bedside Translation Pertaining to the Identified Susceptibility Alleles and Loci in Ankylosing Spondylitis. Current Rheumatology Reports, 2016, 18, 63.	2.1	6
254	Interleukin 27. , 2016, , 749-759.		0
255	Insights on methotrexate in psoriatic disease. Clinical Immunology, 2016, 172, 61-64.	1.4	10
256	Review: Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases. Arthritis and Rheumatology, 2016, 68, 35-45.	2.9	187
257	The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment. Clinical and Experimental Immunology, 2015, 183, 30-36.	1.1	83
258	Secukinumab for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2016, 12, 1027-1036.	1.3	7
259	Molecular and pathogenic effects of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in MHC-I-associated inflammatory disorders: Towards a unifying view. Molecular Immunology, 2016, 77, 193-204.	1.0	86
260	Imaging Evaluation of the Entheses. Rheumatic Disease Clinics of North America, 2016, 42, 679-693.	0.8	27
261	Secukinumab: a promising therapeutic option in spondyloarthritis. Clinical Rheumatology, 2016, 35, 2151-2161.	1.0	2
262	IL-17-producing Î³Î´ T cells enhance bone regeneration. Nature Communications, 2016, 7, 10928.	5.8	271
263	Differential mechanisms of de-regulated bone formation in rheumatoid arthritis and spondyloarthritis. Rheumatology, 2016, 55, ii56-ii60.	0.9	16

#	Article	IF	Citations
264	New treatment targets for axial spondyloarthritis: Table 1. Rheumatology, 2016, 55, ii38-ii42.	0.9	21
265	Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis. Current Rheumatology Reports, 2016, 18, 72.	2.1	10
266	Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling. Science Signaling, 2016, 9, ra28.	1.6	44
267	Idiopathic Thrombocytopenic Purpura. , 2016, , 595-604.		0
268	Rebamipide prevents peripheral arthritis and intestinal inflammation by reciprocally regulating Th17/Treg cell imbalance in mice with curdlan-induced spondyloarthritis. Journal of Translational Medicine, 2016, 14, 190.	1.8	15
270	Ustekinumab as a Therapeutic Option for Children With Refractory Enthesitis-Related Arthritis. Journal of Clinical Rheumatology, 2016, 22, 282-284.	0.5	19
271	Proâ€inflammatory selfâ€reactive TÂcells are found within murine TCRâ€Î±Î²⁺CD4^{â^'}CD8^{â^'}PDâ€1⁺ cells. European Journal of Immunology, 2016, 46, 1383-1391.	1.6	36
272	AhR modulates the ILâ€22â€producing cell proliferation/recruitment in imiquimodâ€induced psoriasis mouse model. European Journal of Immunology, 2016, 46, 1449-1459.	1.6	36
273	Biologic agents in juvenile spondyloarthropathies. Pediatric Rheumatology, 2016, 14, 17.	0.9	21
274	IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients. Arthritis Research and Therapy, 2016, 18, 52.	1.6	35
275	Detection of novel diagnostic antibodies in ankylosing spondylitis: An overview. Autoimmunity Reviews, 2016, 15, 820-832.	2.5	39
276	Ankylosing Spondylitis and Axial Spondyloarthritis. New England Journal of Medicine, 2016, 374, 2563-2574.	13.9	565
277	Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Annals of the Rheumatic Diseases, 2016, 75, 660-666.	0.5	62
279	Juvenile Psoriatic Arthritis. , 2016, , 256-267.e5.		4
280	Biologic Therapy of Psoriatic Arthritis. , 2016, , 295-308.		4
281	Animal Models of Psoriasis and Psoriatic Arthritis. , 2016, , 103-109.		1
282	Interactions of the Immune System with Skin and Bone Tissue in Psoriatic Arthritis: A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2016, 51, 87-99.	2.9	31
283	Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases. Annual Review of Medicine, 2016, 67, 337-353.	5.0	159

#	Article	IF	Citations
284	Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy, 2016, 16, 711-722.	1.4	22
285	LLLT for the management of patients with ankylosing spondylitis. Lasers in Medical Science, 2016, 31, 459-469.	1.0	7
286	Distinct immune signatures in the colon of Crohn's disease and ankylosing spondylitis patients in the absence of inflammation. Immunology and Cell Biology, 2016, 94, 421-429.	1.0	7
287	Cytokine Pathways in Psoriasis and Psoriatic Arthritis. , 2016, , 73-82.		4
288	An ankylosing spondylitis-associated genetic variant in theIL23R-IL12RB2intergenic region modulates enhancer activity and is associated with increased Th1-cell differentiation. Annals of the Rheumatic Diseases, 2016, 75, 2150-2156.	0.5	45
289	ATP-Induced Inflammation Drives Tissue-Resident Th17 Cells in Metabolically Unhealthy Obesity. Journal of Immunology, 2016, 196, 3287-3296.	0.4	88
290	Gut inflammation and microbiome in spondyloarthritis. Rheumatology International, 2016, 36, 457-468.	1.5	14
291	Psoriatic Arthritis and Psoriasis. , 2016, , .		3
292	Focal bone involvement in inflammatory arthritis: the role of IL17. Rheumatology International, 2016, 36, 469-482.	1.5	40
293	The role of the unfolded protein response in axial spondyloarthritis. Clinical Rheumatology, 2016, 35, 1425-1431.	1.0	12
294	An overview of investigational new drugs for treating ankylosing spondylitis. Expert Opinion on Investigational Drugs, 2016, 25, 95-104.	1.9	14
295	Mediators of inflammation and bone remodeling in rheumatic disease. Seminars in Cell and Developmental Biology, 2016, 49, 2-10.	2.3	74
296	Macrophage Polarization and Bone Formation: A review. Clinical Reviews in Allergy and Immunology, 2016, 51, 79-86.	2.9	152
297	Presence of HLA-B27 is associated with changes of serum levels of mediators of the Wnt and hedgehog pathway. Joint Bone Spine, 2016, 83, 43-46.	0.8	16
298	Ankylosing spondylitis patients display altered dendritic cell and T cell populations that implicate pathogenic roles for the IL-23 cytokine axis and intestinal inflammation. Rheumatology, 2016, 55, 120-132.	0.9	32
299	What can immunophenotyping of T and dendritic cells teach us about the pathophysiology of ankylosing spondylitis?. Rheumatology, 2016, 55, 4-5.	0.9	0
300	Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts. Clinical Reviews in Allergy and Immunology, 2016, 51, 1-15.	2.9	88
301	HLA-B27 and psoriatic disease: a modern view of an old relationship. Rheumatology, 2016, 55, 221-229.	0.9	56

#	Article	IF	Citations
302	Aortitis por arteritis de cÃ©lulas gigantes y artritis psoriÃ¡sica: una asociaciÃ³n infrecuente. ReumatologÃa ClÃnica, 2017, 13, 230-232.	0.2	1
303	New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents. Expert Opinion on Pharmacotherapy, 2017, 18, 275-282.	0.9	8
304	Axial spondyloarthritis. Lancet, The, 2017, 390, 73-84.	6.3	876
305	T cell responses in the central nervous system. Nature Reviews Immunology, 2017, 17, 179-194.	10.6	219
306	Potential route of Th17/T_{reg}cell dynamics in targeting type 1 diabetes and rheumatoid arthritis: an autoimmune disorder perspective. British Journal of Biomedical Science, 2017, 74, 8-15.	1.2	12
307	Inflammatory mechanisms in tendinopathy â€“ towards translation. Nature Reviews Rheumatology, 2017, 13, 110-122.	3.5	269
308	Review: Innate Lymphoid Cells: Sparking Inflammatory Rheumatic Disease?. Arthritis and Rheumatology, 2017, 69, 885-897.	2.9	13
309	Artritis psoriÃ¡sica. Medicine, 2017, 12, 1508-1519.	0.0	0
310	A20 inhibition of STAT1 expression in myeloid cells: a novel endogenous regulatory mechanism preventing development of enthesitis. Annals of the Rheumatic Diseases, 2017, 76, 585-592.	0.5	66
311	Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Annals of the Rheumatic Diseases, 2017, 76, 1070-1077.	0.5	213
313	Psoriatic Arthritis. New England Journal of Medicine, 2017, 376, 957-970.	13.9	931
314	Structural Disease Progression in Axial Spondyloarthritis: Still a Cause for Concern?. Current Rheumatology Reports, 2017, 19, 14.	2.1	18
315	Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Research and Therapy, 2017, 19, 51.	1.6	58
316	The role of IL 23 in the treatment of psoriasis. Expert Review of Clinical Immunology, 2017, 13, 525-534.	1.3	111
317	The Human Leukocyte Antigen (HLA)-B27 Peptidome in Vivo, in Spondyloarthritis-susceptible HLA-B27 Transgenic Rats and the Effect of Erap1 Deletion. Molecular and Cellular Proteomics, 2017, 16, 642-662.	2.5	50
318	IL-17 and IFN-Î³ producing NK and Î³Î´-T cells are preferentially expanded in synovial fluid of patients with reactive arthritis and undifferentiated spondyloarthritis. Clinical Immunology, 2017, 183, 207-212.	1.4	40
319	Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis. Current Opinion in Rheumatology, 2017, 29, 287-292.	2.0	25
320	Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases. Journal of Rheumatology, 2017, 44, 1011-1017.	1.0	15

#	Article	IF	Citations
322	Basic and Translational Science: A Report from the GRAPPA 2016 Annual Meeting. Journal of Rheumatology, 2017, 44, 679-683.	1.0	2
323	The role of IL-17 in the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2017, 13, 815-821.	1.3	10
324	Arthritis, Arthropathy, and Osteoporosis in Inflammatory Bowel Disease. , 2017, , 571-583.		0
325	Pathogenesis of ankylosing spondylitis â€" recent advances and future directions. Nature Reviews Rheumatology, 2017, 13, 359-367.	3.5	238
326	Causes and consequences of endoplasmic reticulum stress in rheumatic disease. Nature Reviews Rheumatology, 2017, 13, 25-40.	3.5	81
328	Cellular Stress in the Context of an Inflammatory Environment Supports TGF-Î²-Independent T Helper-17 Differentiation. Cell Reports, 2017, 19, 2357-2370.	2.9	59
329	Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis. Arthritis and Rheumatology, 2017, 69, 1816-1822.	2.9	121
331	Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis. Arthritis and Rheumatology, 2017, 69, 1796-1806.	2.9	61
332	Structural studies unravel the active conformation of apo RORÎ³t nuclear receptor and a common inverse agonism of two diverse classes of RORÎ³t inhibitors. Journal of Biological Chemistry, 2017, 292, 11618-11630.	1.6	47
333	The dichotomous nature of T helper 17 cells. Nature Reviews Immunology, 2017, 17, 535-544.	10.6	318
334	Developments with experimental and investigational drugs for axial spondyloarthritis. Expert Opinion on Investigational Drugs, 2017, 26, 833-842.	1.9	1
335	Why location matters â€" site-specific factors in rheumatic diseases. Nature Reviews Rheumatology, 2017, 13, 433-442.	3.5	34
336	The Paradox of Bone Formation and Bone Loss in Ankylosing Spondylitis: Evolving New Concepts of Bone Formation and Future Trends in Management. Current Rheumatology Reports, 2017, 19, 17.	2.1	37
337	Aortitis due to Giant Cell Arteritis and Psoriatic Arthritis: An Uncommon Association. ReumatologÃa ClÃnica (English Edition), 2017, 13, 230-232.	0.2	1
338	Ankylosing Spondylitis: HLA-B*27-Positive Versus HLA-B*27-Negative Disease. Current Rheumatology Reports, 2017, 19, 26.	2.1	37
339	Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. Journal of Rheumatology, 2017, 44, 599-608.	1.0	39
340	Clinical Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence, Characteristics, and Outcome. Arthritis Care and Research, 2017, 69, 1685-1691.	1.5	108
341	Mesenchymal stem cells provide novel insights into ankylosing spondylitis. Journal of Molecular Medicine, 2017, 95, 119-121.	1.7	0

#	Article	IF	Citations
343	A two-amino-acid substitution in the transcription factor RORÎ³t disrupts its function in TH17 differentiation but not in thymocyte development. Nature Immunology, 2017, 18, 1128-1138.	7.0	44
344	Inflammatory diseases and bone fragility. Osteoporosis International, 2017, 28, 3301-3314.	1.3	132
345	IL-1Î² and IL-23 Promote Extrathymic Commitment of CD27+CD122â^' Î³Î´ T Cells to Î³ÎT17 Cells. Journal of Immunology, 2017, 199, 2668-2679.	0.4	51
346	A novel role for bone-derived cells in ankylosing spondylitis: Focus on IL-23. Biochemical and Biophysical Research Communications, 2017, 491, 787-793.	1.0	12
347	Mechanism of New Bone Formation in Axial Spondyloarthritis. Current Rheumatology Reports, 2017, 19, 55.	2.1	58
348	Differential expression of alarminsâ€"S100A9, IL-33, HMGB1 and HIF-1Î± in supraspinatus tendinopathy before and after treatment. BMJ Open Sport and Exercise Medicine, 2017, 3, e000225.	1.4	25
349	Targeting Inflammation in Rotator Cuff Tendon Degeneration and Repair. Techniques in Shoulder and Elbow Surgery, 2017, 18, 84-90.	0.2	34
350	Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. Physiological Reviews, 2017, 97, 1295-1349.	13.1	347
351	Les enthÃ©sites. Revue Du Rhumatisme (Edition Francaise), 2017, 84, A21-A28.	0.0	0
352	Enthesitis: from pathophysiology to treatment. Nature Reviews Rheumatology, 2017, 13, 731-741.	3.5	316
353	Osteoimmunology in Bone Fracture Healing. Current Osteoporosis Reports, 2017, 15, 367-375.	1.5	133
354	Investigation of a possible extended risk haplotype in the IL23R region associated with ankylosing spondylitis. Genes and Immunity, 2017, 18, 105-108.	2.2	8
355	Etanercept for treating axial spondyloarthritis. Expert Opinion on Biological Therapy, 2017, 17, 1173-1181.	1.4	15
357	Generation and differentiation of induced pluripotent stem cells reveal ankylosing spondylitis risk gene expression in bone progenitors. Clinical Rheumatology, 2017, 36, 143-154.	1.0	17
358	Lessons Learned From Trials Targeting Cytokine Pathways inÂPatients With Inflammatory Bowel Diseases. Gastroenterology, 2017, 152, 374-388.e4.	0.6	108
359	<scp>IL</scp>â€17: overview and role in oral immunity and microbiome. Oral Diseases, 2017, 23, 854-865.	1.5	130
360	Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmunity Reviews, 2017, 16, 10-15.	2.5	95
361	Pathogenesis of ligaments ossification in spondyloarthritis: insights and doubts. Annals of Medicine, 2017, 49, 196-205.	1.5	10

#	Article	IF	Citations
362	New insights toward the pathogenesis of ankylosing spondylitis; genetic variations and epigenetic modifications. Modern Rheumatology, 2017, 27, 198-209.	0.9	47
363	Ankylosing spondylitis M-CSF-derived macrophages are undergoing unfolded protein response (UPR) and express higher levels of interleukin-23. Modern Rheumatology, 2017, 27, 862-867.	0.9	23
364	Progress of genomeâ€wide association studies of ankylosing spondylitis. Clinical and Translational Immunology, 2017, 6, e163.	1.7	42
366	IL-36Î³ inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis. International Journal of Medical Sciences, 2017, 14, 1002-1007.	1.1	75
367	IL-23 and Th17 Disease in Inflammatory Arthritis. Journal of Clinical Medicine, 2017, 6, 81.	1.0	51
368	Genetic and Functional Associations with Decreased Anti-inflammatory Tumor Necrosis Factor Alpha Induced Protein 3 in Macrophages from Subjects with Axial Spondyloarthritis. Frontiers in Immunology, 2017, 8, 860.	2.2	9
369	Anti-IL17A in Axial Spondyloarthritisâ€"Where Are We At?. Frontiers in Medicine, 2017, 4, 1.	1.2	60
370	Different Modulatory Effects of IL-17, IL-22, and IL-23 on Osteoblast Differentiation. Mediators of Inflammation, 2017, 2017, 1-11.	1.4	38
371	The role of HLA-B*27 in spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2017, 31, 797-815.	1.4	39
372	Biology, Physiology, and Morphology of Bone. , 2017, , 60-65.		0
373	Etiology and Pathogenesis of Spondyloarthritis. , 2017, , 1245-1255.e4.		4
376	The SKG model of spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2017, 31, 895-909.	1.4	22
377	Uveitis in the Spondyloarthopathies. Best Practice and Research in Clinical Rheumatology, 2017, 31, 846-862.	1.4	57
378	Th17 cell responses in spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2017, 31, 777-796.	1.4	21
379	Born to run: The paradox of biomechanical force in spondyloarthritis from an evolutionary perspective. Best Practice and Research in Clinical Rheumatology, 2017, 31, 887-894.	1.4	20
380	Evolving concepts of new bone formation in axial spondyloarthritis: Insights from animal models and human studies. Best Practice and Research in Clinical Rheumatology, 2017, 31, 877-886.	1.4	20
381	Vitamin D Deficiency in Axial Spondyloarthritis is Associated With Higher Disease Activity. Archives of Rheumatology, 2017, 32, 209-215.	0.3	14
382	Spondyloarthritides. , 2017, , 189-211.		0

#	Article	IF	Citations
383	Recent advances in understanding spondyloarthritis. F1000Research, 2017, 6, 304.	0.8	2
384	A review of ustekinumab in the treatment of psoriatic arthritis. Immunotherapy, 2018, 10, 361-372.	1.0	15
385	Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton. Calcified Tissue International, 2018, 102, 607-618.	1.5	44
386	Psoriatic arthritis: tissue-directed inflammation?. Clinical Rheumatology, 2018, 37, 859-868.	1.0	21
387	Emerging drugs for the treatment of axial spondyloarthritis. Expert Opinion on Emerging Drugs, 2018, 23, 83-96.	1.0	9
388	New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. Therapeutic Advances in Chronic Disease, 2018, 9, 77-87.	1.1	40
389	STAT-3â€“independent production of IL-17 by mouse innate-like Î±Î² T cells controls ocular infection. Journal of Experimental Medicine, 2018, 215, 1079-1090.	4.2	25
390	Interaction between microbiome and host genetics in psoriatic arthritis. Autoimmunity Reviews, 2018, 17, 276-283.	2.5	38
391	Shifting the focus â€“ the primary role of <scp>IL</scp>â€23 in psoriasis and other inflammatory disorders. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1111-1119.	1.3	80
392	The role of gut microbiota and IL-23/IL-17 pathway in ankylosing spondylitis immunopathogenesis: New insights and updates. Immunology Letters, 2018, 196, 52-62.	1.1	59
393	Augmented Th17 Differentiation Leads to Cutaneous and SynovioâEntheseal Inflammation in a Novel Model of Psoriatic Arthritis. Arthritis and Rheumatology, 2018, 70, 855-867.	2.9	29
394	Spondyloarthritis features in zymosan-induced SKG mice. Joint Bone Spine, 2018, 85, 583-591.	0.8	12
395	Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions. Calcified Tissue International, 2018, 102, 559-574.	1.5	41
396	Effectiveness and safety of ustekinumab in naÃ¯ve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clinical Rheumatology, 2018, 37, 397-405.	1.0	36
397	Enthesitis: A hallmark of psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2018, 48, 35-43.	1.6	126
398	A case of ankylosing spondylitis with concurrent Takayasu arteritis. Journal of International Medical Research, 2018, 46, 2486-2494.	0.4	4
399	Fecal transplants in spondyloarthritis and uveitis: ready for a clinical trial?. Current Opinion in Rheumatology, 2018, 30, 303-309.	2.0	18
400	Dactylitis: A hallmark of psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2018, 48, 263-273.	1.6	88

#	Article	IF	Citations
401	The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology, 2018, 57, 32-40.	0.9	93
402	Spondyloarthritis: An expanding cast of cellular actors. Joint Bone Spine, 2018, 85, 1-3.	0.8	11
404	Solving the pathogenesis of ankylosing spondylitis. Clinical Immunology, 2018, 186, 46-50.	1.4	9
405	The role of innate lymphoid cells in health and disease. Journal of Cellular Physiology, 2018, 233, 4512-4529.	2.0	37
406	Hierarchical, imbalanced pro-inflammatory cytokine networks govern the pathogenesis of chronic arthropathies. Osteoarthritis and Cartilage, 2018, 26, 7-17.	0.6	43
407	Bone Disease in Axial Spondyloarthritis. Calcified Tissue International, 2018, 102, 547-558.	1.5	24
408	New treatment paradigms in spondyloarthritis. Current Opinion in Rheumatology, 2018, 30, 79-86.	2.0	8
409	Recomendaciones de la Sociedad EspaÃ±ola de ReumatologÃa sobre el uso de terapias biolÃ³gicas en espondiloartritis axial. ReumatologÃa ClÃnica, 2018, 14, 320-333.	0.2	24
410	Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis. Expert Opinion on Biological Therapy, 2018, 18, 101-107.	1.4	27
411	Innately versatile: Î³Î´17ÂT cells in inflammatory and autoimmune diseases. Journal of Autoimmunity, 2018, 87, 26-37.	3.0	93
412	The Diagnostic and Prognostic Role of Interleukin 12B and Interleukin 6R Gene Polymorphism in Patients With Ankylosing Spondylitis. Journal of Clinical Rheumatology, 2018, 24, 18-24.	0.5	8
413	The role of ILâ€23 receptor signaling in inflammationâ€mediated erosive autoimmune arthritis and bone remodeling. European Journal of Immunology, 2018, 48, 220-229.	1.6	23
414	Opportunities and challenges in the treatment of psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 440-452.	1.4	11
415	Emerging treatment options for spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 472-484.	1.4	15
416	Recent advances in ankylosing spondylitis: understanding the disease and management. F1000Research, 2018, 7, 1512.	0.8	77
417	Disease modification in axial spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 427-439.	1.4	10
418	Advances in understanding the pathophysiology of spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 331-341.	1.4	23
419	Entesitis, una manifestaciÃ³n clÃnica con muchas incÃ³gnitas. Revista Colombiana De ReumatologÃa, 2018, 25, 221-223.	0.0	0

#	Article	IF	Citations
420	Enthesitis, a clinical manifestation with many unknowns. Revista Colombiana De ReumatologÃa (English Edition), 2018, 25, 221-223.	0.1	0
421	Pathogenic stromal cells as therapeutic targets in joint inflammation. Nature Reviews Rheumatology, 2018, 14, 714-726.	3.5	81
422	Update on the epidemiology, risk factors, and disease outcomes of axial spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 241-253.	1.4	27
423	Recommendations by the Spanish Society of Rheumatology on the Use of Biological Therapies in Axial Spondyloarthritis. ReumatologÃa ClÃnica (English Edition), 2018, 14, 320-333.	0.2	3
424	Sumoylation of RORÎ³t regulates TH17 differentiation and thymocyte development. Nature Communications, 2018, 9, 4870.	5.8	22
425	Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis. Frontiers in Immunology, 2018, 9, 2901.	2.2	58
426	Progress in our understanding of the pathogenesis of ankylosing spondylitis. Rheumatology, 2018, 57, vi4-vi9.	0.9	100
427	MAIT cells: potent major cellular players in the IL-17 pathway of spondyloarthritis?. RMD Open, 2018, 4, e000821.	1.8	19
428	Genetics and Functional Genomics of Spondyloarthritis. Frontiers in Immunology, 2018, 9, 2933.	2.2	47
429	The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science. Frontiers in Immunology, 2018, 9, 2668.	2.2	73
430	Silencing SOCS3 Markedly Deteriorates Spondyloarthritis in Mice Induced by Minicircle DNA Expressing IL23. Frontiers in Immunology, 2018, 9, 2641.	2.2	7
431	Effects of the IL-23â€“IL-17 pathway onÂbone in spondyloarthritis. Nature Reviews Rheumatology, 2018, 14, 631-640.	3.5	154
432	Abatacept for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2018, 14, 899-905.	1.3	7
433	Disease activity assessment in patients with psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 401-414.	1.4	17
434	The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis. Frontiers in Immunology, 2018, 9, 2226.	2.2	51
435	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet, The, 2018, 392, 2441-2451.	6.3	251
436	The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis. Therapeutic Advances in Musculoskeletal Disease, 2018, 10, 169-180.	1.2	16
437	Genetically determined high activities of the TNF-alpha, IL23/IL17, and NFkB pathways were associated with increased risk of ankylosing spondylitis. BMC Medical Genetics, 2018, 19, 165.	2.1	44

#	Article	IF	Citations
438	The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling. Frontiers in Immunology, 2018, 9, 1550.	2.2	65
439	The role of RORÎ± in salivary gland lesions in patients with primary SjÃ¶grenâ€™s syndrome. Arthritis Research and Therapy, 2018, 20, 205.	1.6	12
440	Diet Modifies Colonic Microbiota and CD4+ T-Cell Repertoire to Induce Flares of Colitis in Mice With Myeloid-Cell Expression of Interleukin 23. Gastroenterology, 2018, 155, 1177-1191.e16.	0.6	32
441	Beyond the TNF-Î± Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology. Drugs, 2018, 78, 1397-1418.	4.9	16
442	Altered cytokine expression by macrophages from HLA-B27-positive spondyloarthritis patients without evidence of endoplasmic reticulum stress. Rheumatology Advances in Practice, 2018, 2, rky014.	0.3	12
443	Role of innate immune system in the pathogenesis of ankylosing spondylitis. Biomedicine and Pharmacotherapy, 2018, 105, 130-143.	2.5	48
445	Enthesitis: Much More Than Focal Insertion Point Inflammation. Current Rheumatology Reports, 2018, 20, 41.	2.1	69
446	The pathogenesis of psoriatic arthritis. Lancet, The, 2018, 391, 2273-2284.	6.3	347
447	Psoriatic arthritis: novel targets add to a therapeutic renaissance. Lancet, The, 2018, 391, 2187-2189.	6.3	6
448	Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet, The, 2018, 391, 2213-2224.	6.3	159
449	Complex role of IL-23R polymorphisms on ankylosing spondylitis: a meta-analysis. Expert Review of Clinical Immunology, 2018, 14, 635-643.	1.3	12
450	Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies. Mediators of Inflammation, 2018, 2018, 1-8.	1.4	30
451	Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study. Arthritis Research and Therapy, 2018, 20, 153.	1.6	60
452	Increased IL-22- and IL-17A-Producing Mucosal-Associated Invariant T Cells in the Peripheral Blood of Patients With Ankylosing Spondylitis. Frontiers in Immunology, 2018, 9, 1610.	2.2	59
453	A model of chronic enthesitis and new bone formation characterized by multimodal imaging. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	8
454	Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. International Journal of Molecular Sciences, 2018, 19, 530.	1.8	142
455	Regulation of Cytokine Production by the Unfolded Protein Response; Implications for Infection and Autoimmunity. Frontiers in Immunology, 2018, 9, 422.	2.2	127
456	Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Frontiers in Immunology, 2018, 9, 579.	2.2	201

#	Article	IF	Citations
457	Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing Î³Î´ T Cells, Î±Î² T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis. Frontiers in Immunology, 2018, 9, 885.	2.2	26
458	T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities. Frontiers in Immunology, 2018, 9, 1390.	2.2	70
459	It Takes â€œGutsâ€•to Cause Joint Inflammation: Role of Innate-Like T Cells. Frontiers in Immunology, 2018, 9, 1489.	2.2	31
460	Role of Stem Cells in Pathophysiology and Therapy of Spondyloarthropathiesâ€"New Therapeutic Possibilities?. International Journal of Molecular Sciences, 2018, 19, 80.	1.8	16
462	IL-17 in the immunopathogenesis of spondyloarthritis. Nature Reviews Rheumatology, 2018, 14, 453-466.	3.5	102
463	Pathogenic role of tissue-resident memory T cells in autoimmune diseases. Autoimmunity Reviews, 2018, 17, 906-911.	2.5	67
464	IL-23 Inhibitors for Psoriasis. Current Dermatology Reports, 2018, 7, 119-124.	1.1	3
465	Translating GWAS in rheumatic disease: approaches to establishing mechanism and function for genetic associations with ankylosing spondylitis. Briefings in Functional Genomics, 2018, 17, 308-318.	1.3	6
466	Enthesitis and Dactylitis in Psoriatic Disease: A Guide for Dermatologists. American Journal of Clinical Dermatology, 2018, 19, 839-852.	3.3	39
467	Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Annals of the Rheumatic Diseases, 2018, 77, 1295-1302.	0.5	275
468	Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis. Annals of the Rheumatic Diseases, 2018, 77, 1815-1824.	0.5	38
469	FOXP3, RORÎ³t and IL-10 cytokine profile in chronic heart failure. Bratislava Medical Journal, 2018, 118, 637-641.	0.4	9
470	The use of biomarkers as a tool for novel psoriatic disease drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 875-887.	2.5	6
471	Disease Modification in Psoriatic Arthritis. Current Treatment Options in Rheumatology, 2018, 4, 197-213.	0.6	0
472	Imaging Anatomy: Magnetic Resonance Imaging, Computed Tomography, Positron Emission Tomography and Other Novel Imaging Techniques. , 2018, , 65-83.		0
473	Conditional deletion of RB1 in the Tie2 lineage leads to aortic valve regurgitation. PLoS ONE, 2018, 13, e0190623.	1.1	4
474	Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics. Current Opinion in Rheumatology, 2018, 30, 526-532.	2.0	27
475	Stress proteins in the pathogenesis of spondyloarthritis. Rheumatology International, 2019, 39, 595-604.	1.5	2

#	Article	IF	Citations
476	Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Seminars in Arthritis and Rheumatism, 2019, 48, 632-637.	1.6	106
477	Constitutive overexpression of TNF in BPSM1 mice causes iBALT and bone marrow nodular lymphocytic hyperplasia. Immunology and Cell Biology, 2019, 97, 29-38.	1.0	2
478	Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review. Cells, 2019, 8, 818.	1.8	101
479	Enthesopathy and involvement of synovio-entheseal complex in systemic sclerosis: an ultrasound pilot study. Rheumatology, 2019, 59, 580-585.	0.9	6
480	Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review. Internal Medicine, 2019, 58, 2839-2843.	0.3	8
481	Cytokine-Induced and Stretch-Induced Sphingosine 1-Phosphate Production by Enthesis Cells Could Favor Abnormal Ossification in Spondyloarthritis. Journal of Bone and Mineral Research, 2019, 34, 2264-2276.	3.1	24
482	Current Unmet Needs in Spondyloarthritis. Current Rheumatology Reports, 2019, 21, 43.	2.1	24
483	The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Annals of the Rheumatic Diseases, 2019, 78, 1167-1178.	0.5	152
484	The IL-23/IL-17 pathway in human chronic inflammatory diseases â€“ new insight from genetics and targeted therapies. Microbes and Infection, 2019, 21, 246-253.	1.0	14
485	Innate-like T cells in children with sickle cell disease. PLoS ONE, 2019, 14, e0219047.	1.1	4
486	Ixekizumab for treating ankylosing spondylitis. Immunotherapy, 2019, 11, 1273-1282.	1.0	6
487	The Pathogenesis of Ankylosing Spondylitis: an Update. Current Rheumatology Reports, 2019, 21, 58.	2.1	67
488	Therapeutic Vaccines as Novel Immunotherapy. , 2019, , .		1
489	Advances in nanomedicine for the treatment of ankylosing spondylitis . International Journal of Nanomedicine, 2019, Volume 14, 8521-8542.	3.3	22
490	Antiâ€tumor necrosis factor treatment increases both the Th17 and Th22 T helper subsets in spondyloarthritis. Apmis, 2019, 127, 789-796.	0.9	3
491	Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis. Frontiers in Pharmacology, 2019, 10, 872.	1.6	65
492	Bedside to bench: defining the immunopathogenesis of psoriatic arthritis. Nature Reviews Rheumatology, 2019, 15, 645-656.	3.5	37
493	Implication of IL-17 in Bone Loss and Structural Damage in Inflammatory Rheumatic Diseases. Mediators of Inflammation, 2019, 2019, 1-9.	1.4	37

#	Article	IF	Citations
494	Biological and synthetic target DMARDs in psoriatic arthritis. Pharmacological Research, 2019, 149, 104473.	3.1	16
495	Evidence that tissue resident human enthesis Î³ÎT-cells can produce IL-17A independently of IL-23R transcript expression. Annals of the Rheumatic Diseases, 2019, 78, 1559-1565.	0.5	109
496	The IL-23â€“IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nature Reviews Rheumatology, 2019, 15, 747-757.	3.5	78
497	RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitisâ€”Novel Targets for Therapy?. Frontiers in Immunology, 2018, 9, 3132.	2.2	21
498	Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation. Nature Communications, 2019, 10, 549.	5.8	28
499	Pharmacological management of axial spondyloarthritis in adults. Expert Opinion on Pharmacotherapy, 2019, 20, 1483-1491.	0.9	9
500	The effect of anti-IL-6 receptor antibody for the treatment of McH-lpr/lpr-RA1 mice that spontaneously developed destructive arthritis and enthesitis. BMC Musculoskeletal Disorders, 2019, 20, 286.	0.8	9
501	The Intestine Harbors Functionally Distinct Homeostatic Tissue-Resident and Inflammatory Th17 Cells. Immunity, 2019, 51, 77-89.e6.	6.6	220
502	Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 135.	1.6	27
503	Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis. Current Rheumatology Reports, 2019, 21, 35.	2.1	11
504	An update on pathogenesis of psoriatic arthritis and potential therapeutic targets. Expert Review of Clinical Immunology, 2019, 15, 823-836.	1.3	31
505	Osteoimmunology: evolving concepts in boneâ€“immune interactions in health and disease. Nature Reviews Immunology, 2019, 19, 626-642.	10.6	402
506	IL-7 is a Key Driver Cytokine in Spondyloarthritis?. Journal of Immunology Research, 2019, 2019, 1-7.	0.9	6
507	ILC3 in Axial Spondyloarthritis: the Gut Angle. Current Rheumatology Reports, 2019, 21, 37.	2.1	26
508	A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab. Drugs - Real World Outcomes, 2019, 6, 83-91.	0.7	5
509	Characterization of psoriasiform dermatitis induced by systemic injection of interleukinâ€23 minicircles in mice. Journal of Dermatology, 2019, 46, 482-497.	0.6	12
510	Psoriatic Arthritis: What is Happening at the Joint?. Rheumatology and Therapy, 2019, 6, 305-315.	1.1	40
511	Fecal Calprotectin, Gut Inflammation and Spondyloarthritis. Archives of Medical Research, 2019, 50, 41-46.	1.5	17

#	Article	IF	Citations
512	The IL-23/IL-17 pathway in human chronic inflammatory diseasesâ€"new insight from genetics and targeted therapies. Genes and Immunity, 2019, 20, 415-425.	2.2	38
513	Serum miR-21 expression correlates with radiographic progression but also low bone mineral density in patients with ankylosing spondylitis: a cross-sectional study. Innate Immunity, 2019, 25, 314-321.	1.1	12
514	Identification of myeloid cells in the human enthesis as the main source of local IL-23 production. Annals of the Rheumatic Diseases, 2019, 78, 929-933.	0.5	70
515	The Gut Microbiome and Ankylosing Spondylitis. , 2019, , 87-95.		1
516	Pathogenesis of Ankylosing Spondylitis. , 2019, , 97-110.		0
517	Bone Pathophysiology in Axial Spondyloarthritis. , 2019, , 111-120.		0
518	Comorbidities. , 2019, , 183-202.		1
519	Comparative study on serumâ€induced arthritis in the temporomandibular and limb joint of mice. International Journal of Rheumatic Diseases, 2019, 22, 636-645.	0.9	3
520	Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Review of Clinical Immunology, 2019, 15, 589-597.	1.3	12
521	The Effect of TNF Inhibition on Bone Density and Fracture Risk and of IL17 Inhibition on Radiographic Progression and Bone Density in Patients with Axial Spondyloarthritis: a Systematic Literature Review. Current Rheumatology Reports, 2019, 21, 20.	2.1	19
522	Aortic-vertebral interaction in ankylosing spondylitis: syndesmophyte development at the juxta-aortic vertebral rim. Annals of the Rheumatic Diseases, 2019, 78, 922-928.	0.5	6
523	Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. Frontiers in Immunology, 2019, 10, 382.	2.2	62
524	Vedolizumab for inflammatory bowel disease: a two-edge sword in the gut-joint/enthesis axis. Rheumatology, 2019, 58, 937-939.	0.9	6
525	Disruption of Protein Homeostasis and Activation of Cellular Stress Pathways in Autoinflammation. , 2019, , 137-147.		0
526	Genetic and inflammatory factors associated with psoriatic arthritis: Relevance to diagnosis and management. Clinical Immunology, 2019, 202, 59-75.	1.4	10
527	Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nature Reviews Rheumatology, 2019, 15, 153-166.	3.5	208
528	Treating to Target(s) With Interleukin-17 Inhibitors. Journal of Cutaneous Medicine and Surgery, 2019, 23, 3S-34S.	0.6	6
529	Enthesitis-related arthritis: current perspectives . Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 19-31.	0.8	27

#	Article	IF	Citations
530	Loss of Regulatory Immune Function in Coronary Artery Disease Patients from the Indian Population. Journal of Cardiovascular Translational Research, 2019, 12, 378-388.	1.1	3
531	The role of ERAP1 in autoinflammation and autoimmunity. Human Immunology, 2019, 80, 302-309.	1.2	17
532	Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis. PLoS ONE, 2019, 14, e0212043.	1.1	23
533	Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study. RMD Open, 2019, 5, e001053.	1.8	11
534	Bone formation in axial spondyloarthritis: Is disease modification possible?. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101491.	1.4	12
535	Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23. Cancer Discovery, 2019, 9, 1511-1519.	7.7	26
536	Efficacy of ustekinumab in biologic-naÃ¯ve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. RMD Open, 2019, 5, e000990.	1.8	17
537	Assessment of Enthesitis in Psoriatic Arthritis. Journal of Rheumatology, 2019, 46, 869-870.	1.0	10
539	Three Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 258-270.	2.9	237
540	Active and chronic sacroiliitis, spondylitis and enthesitis, How specific are imaging findings for axial spondyloarthritis?. Rheumatology, 2019, 58, 1321-1324.	0.9	12
541	The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Review of Clinical Immunology, 2019, 15, 123-134.	1.3	54
542	RORÎ³t inhibition selectively targets IL-17 producing iNKT and Î³Î´-T cells enriched in Spondyloarthritis patients. Nature Communications, 2019, 10, 9.	5.8	255
543	Pathophysiology, assessment and treatment of psoriatic dactylitis. Nature Reviews Rheumatology, 2019, 15, 113-122.	3.5	45
544	The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. Journal of Crohn's and Colitis, 2019, 13, 541-554.	0.6	112
545	The genetics, structure and function of the M1 aminopeptidase oxytocinase subfamily and their therapeutic potential in immune-mediated disease. Human Immunology, 2019, 80, 281-289.	1.2	22
546	Regression of Peripheral Subclinical Enthesopathy in Therapyâ€Naive Patients Treated With Ustekinumab forÂModerateâ€toâ€Severe Chronic Plaque Psoriasis: A Fiftyâ€Twoâ€“Week, Prospective, Openâ€Label Feasibility Study. Arthritis and Rheumatology, 2019, 71, 626-631.	2.9	64
547	Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases. Seminars in Arthritis and Rheumatism, 2019, 48, 1133-1141.	1.6	32
548	Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?. Annals of the Rheumatic Diseases, 2019, 78, 1015-1018.	0.5	77

#	Article	IF	Citations
549	Interleukinâ€17A Inhibition Diminishes Inflammation and New Bone Formation in Experimental Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 612-625.	2.9	87
551	Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy, 2019, 19, 55-64.	1.4	34
552	Expansion of Interleukinâ€22â€“ and Granulocyteâ€“Macrophage Colonyâ€Stimulating Factorâ€“Expressing, but Not Interleukinâ€17Aâ€“Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 392-402.	2.9	30
553	Osteoimmunology. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a031245.	2.9	64
554	The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology, 2019, 58, 197-205.	0.9	68
555	Translocation of dead or alive bacteria from mucosa to joints and epiphyseal bone-marrow: facts and hypotheses. Joint Bone Spine, 2020, 87, 31-36.	0.8	17
556	Management of psoriasis as a systemic disease: what is the evidence?. British Journal of Dermatology, 2020, 182, 840-848.	1.4	231
557	Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. Journal of Rheumatology, 2020, 47, 539-547.	1.0	16
558	Differential expression of TLR2 and TLR4 in Î±4Î²7-positive leukocytes of patients with axial spondyloarthritis. Rheumatology, 2020, 59, 879-888.	0.9	3
560	Absolute Rheumatology Review. , 2020, , .		1
562	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmunity Reviews, 2020, 19, 102429.	2.5	197
563	The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. Expert Opinion on Drug Safety, 2020, 19, 69-82.	1.0	10
564	Interleukin-17 cytokines: Effectors and targets in psoriasisâ€”A breakthrough in understanding and treatment. Journal of Experimental Medicine, 2020, 217, .	4.2	54
565	Tackling the autoimmune side in Spondyloarthritis: A systematic review. Autoimmunity Reviews, 2020, 19, 102648.	2.5	13
566	Intestinal and enthesis innate immunity in early axial spondyloarthropathy. Rheumatology, 2020, 59, iv67-iv78.	0.9	17
567	Response to: â€˜Correspondence to â€˜Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expressionâ€™â€™ by Wang and Ma. Annals of the Rheumatic Diseases, 2022, 81, e255-e255.	0.5	4
568	Axial spondyloarthritis: coming of age. Rheumatology, 2020, 59, iv1-iv5.	0.9	4
570	Revisiting the gutâ€“joint axis: links between gut inflammation and spondyloarthritis. Nature Reviews Rheumatology, 2020, 16, 415-433.	3.5	106

#	Article	IF	Citations
571	Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. RMD Open, 2020, 6, e001217.	1.8	19
572	GM-CSF Primes Proinflammatory Monocyte Responses in Ankylosing Spondylitis. Frontiers in Immunology, 2020, 11, 1520.	2.2	16
573	Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies. Frontiers in Immunology, 2020, 11, 591176.	2.2	14
574	Mini-Review: Human Microbiome and Rheumatic Diseases. Frontiers in Cellular and Infection Microbiology, 2020, 10, 491160.	1.8	10
575	Choosing the right treatment for patients with psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2096262.	1.2	14
576	STAT3 phosphorylation inhibition for treating inflammation and new bone formation in ankylosing spondylitis. Rheumatology, 2021, 60, 3923-3935.	0.9	24
577	Bone phenotypes in rheumatology â€“ there is more to bone than just bone. BMC Musculoskeletal Disorders, 2020, 21, 789.	0.8	21
578	Loss and gain of bone in spondyloarthritis: what drives these opposing clinical features?. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2096926.	1.2	21
580	Regeneration of Damaged Tendon-Bone Junctions (Entheses)â€”TAK1 as a Potential Node Factor. International Journal of Molecular Sciences, 2020, 21, 5177.	1.8	14
581	New developments in our understanding of ankylosing spondylitis pathogenesis. Immunology, 2020, 161, 94-102.	2.0	55
582	Peripheral Enthesitis in Spondyloarthritis: Lessons from Targeted Treatments. Drugs, 2020, 80, 1419-1441.	4.9	3
583	Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohnâ€™s Disease: A Case Report and Review of the Literature . Open Access Rheumatology: Research and Reviews, 2020, Volume 12, 133-137.	0.8	5
584	Treatment of Juvenile Spondyloarthritis: Where We Stand. Paediatric Drugs, 2020, 22, 603-615.	1.3	5
585	Resident Memory T Cells. , 2020, , .		1
586	Skin manifestations in spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097591.	1.2	15
587	Children With Enthesitisâ€Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis. Arthritis Care and Research, 2022, 74, 1058-1064.	1.5	18
588	Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice. Scientific Reports, 2020, 10, 8259.	1.6	30
589	Peripheral spondyloarthritis: a neglected entityâ€”state of the art. RMD Open, 2020, 6, e001136.	1.8	42

#	Article	IF	Citations
590	One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opinion on Biological Therapy, 2020, 20, 813-821.	1.4	40
591	Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression. Annals of the Rheumatic Diseases, 2020, 79, 1044-1054.	0.5	56
592	Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literature. Immunotherapy, 2020, 12, 549-554.	1.0	13
593	Beware of wolves in sheep's clothing: immune cell plasticity and instability in health and disease. Annals of the Rheumatic Diseases, 2022, 81, e129-e129.	0.5	1
594	TNF-Î± inhibitor therapy can improve the immune imbalance of CD4+ T cells and negative regulatory cells but not CD8+ T cells in ankylosing spondylitis. Arthritis Research and Therapy, 2020, 22, 149.	1.6	21
595	Efficacy of guselkumab in a subpopulation with pustulotic arthroâ€osteitis through week 52: an exploratory analysis of a phase 3, randomized, doubleâ€blind, placeboâ€controlled study in Japanese patients with palmoplantar pustulosis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2318-2329.	1.3	17
596	Enthesitis in psoriatic arthritis (Part 1): pathophysiology. Rheumatology, 2020, 59, i10-i14.	0.9	14
597	Predicting therapeutic response through biomarker analysis in psoriatic arthritis, an example of precision medicine. Expert Review of Precision Medicine and Drug Development, 2020, 5, 35-42.	0.4	4
598	New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochemical Pharmacology, 2020, 175, 113928.	2.0	51
599	Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2020, 395, 1126-1136.	6.3	206
600	Role of the IL-23 pathway in the pathogenesis and treatment of enthesitis in psoriatic arthritis. Expert Opinion on Biological Therapy, 2020, 20, 787-798.	1.4	6
601	IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. Frontiers in Immunology, 2019, 10, 3096.	2.2	122
603	Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis. Nature Reviews Rheumatology, 2020, 16, 193-207.	3.5	122
604	Interleukinâ€23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy. Immunological Reviews, 2020, 294, 27-47.	2.8	60
605	Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement. Clinical Rheumatology, 2020, 39, 727-736.	1.0	8
606	miR-21 may Act as a Potential Mediator Between Inflammation and Abnormal Bone Formation in Ankylosing Spondylitis Based on TNF-Î± Concentration-Dependent Manner Through the JAK2/STAT3 Pathway. Dose-Response, 2020, 18, 155932581990123.	0.7	14
607	Cutaneous immunohistochemical expression of interleukin-23 receptor (IL-23R) in psoriasis and psoriatic arthritis patients: Relation to musculoskeletal ultrasound findings. Egyptian Rheumatologist, 2020, 42, 313-318.	0.5	6
608	Differential Requirement for CCR6 in IL-23â€“Mediated Skin and Joint Inflammation. Journal of Investigative Dermatology, 2020, 140, 2386-2397.	0.3	8

#	Article	IF	Citations
609	Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study. Clinical Rheumatology, 2020, 39, 2963-2971.	1.0	5
610	A novel treatment for psoriatic arthritis: Janus kinase inhibitors. Chinese Medical Journal, 2020, 133, 959-967.	0.9	17
611	Distal phalangeal bone erosions observed by HR-pQCT in patients with psoriatic onycholysis. Rheumatology, 2021, 60, 1176-1184.	0.9	5
612	Non-radiographic axial spondyloarthritis. Modern Rheumatology, 2021, 31, 277-282.	0.9	9
613	Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo. Annals of the Rheumatic Diseases, 2021, 80, 475-486.	0.5	17
614	Circulating miRNAs in bone health and disease. Bone, 2021, 145, 115787.	1.4	36
615	The causal effect of interleukin-17 on the risk of psoriatic arthritis: a Mendelian randomization study. Rheumatology, 2021, 60, 1963-1973.	0.9	4
616	IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases. Clinical Reviews in Allergy and Immunology, 2021, 60, 31-45.	2.9	14
617	Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults. Expert Review of Clinical Immunology, 2021, 17, 5-13.	1.3	25
618	ILâ€17A expressed on neutrophil extracellular traps promotes mesenchymal stem cell differentiation toward boneâ€forming cells in ankylosing spondylitis. European Journal of Immunology, 2021, 51, 930-942.	1.6	32
619	IL-23 orchestrating immune cell activation in arthritis. Rheumatology, 2021, 60, iv4-iv15.	0.9	9
620	Lessons on SpA pathogenesis from animal models. Seminars in Immunopathology, 2021, 43, 207-219.	2.8	15
621	Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy. Rheumatology, 2021, 60, vi38-vi52.	0.9	7
622	OUP accepted manuscript. Rheumatology, 2021, 60, iv1-iv3.	0.9	7
623	Biologics Targeting Immune Modulation in Inflammatory Disorders. , 2021, , .		0
624	Axial spondyloarthritis: new advances in diagnosis and management. BMJ, The, 2021, 372, m4447.	3.0	71
625	The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis. Frontiers in Immunology, 2020, 11, 596086.	2.2	35
626	Enthesitis-assoziierte Arthritis bei Kindern und Jugendlichen. Springer Reference Medizin, 2021, , 1-10.	0.0	0

#	Article	IF	Citations
627	Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?. Frontiers in Immunology, 2020, 11, 553742.	2.2	29
628	IL-23 and axial disease: do they come together?. Rheumatology, 2021, 60, iv28-iv33.	0.9	13
629	Warum die Hemmung von IL-23 bei ankylosierender Spondylitis nicht wirksam war. Karger Kompass Autoimmun, 2021, 3, 100-107.	0.0	0
630	Research Progress of IL-23/IL-17 Axis in the Pathogenesis and Treatment of Axial Spondyloarthritis. Advances in Clinical Medicine, 2021, 11, 981-989.	0.0	0
631	The enigmatic role of HLA-B*27 in spondyloarthritis pathogenesis. Seminars in Immunopathology, 2021, 43, 235-243.	2.8	18
632	Distinct roles of interleukin-17 and T helper 17Âcells among autoimmune diseases. Journal of Translational Autoimmunity, 2021, 4, 100104.	2.0	16
633	Takayasuâ€™s arteritis occurring under TNF blockers in aÂpatient with spondyloarthritis: is it an association or aÂparadoxical effect?. Reumatologia, 2021, 59, 111-114.	0.5	1
634	Novel immune cell phenotypes in spondyloarthritis pathogenesis. Seminars in Immunopathology, 2021, 43, 265-277.	2.8	23
635	Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open, 2021, 7, e001519.	1.8	32
636	To move or not to move: the paradoxical effect of physical exercise in axial spondyloarthritis. RMD Open, 2021, 7, e001480.	1.8	28
637	Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. Frontiers in Immunology, 2021, 12, 637829.	2.2	140
638	Enthesitis is a clue to the diagnosis of spondyloarthritis, focus on psoriatic arthritis. Sovremennaya Revmatologiya, 2021, 15, 79-86.	0.1	0
639	IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?. Frontiers in Immunology, 2020, 11, 623874.	2.2	16
640	IL-17A and TNF Modulate Normal Human Spinal Entheseal Bone and Soft Tissue Mesenchymal Stem Cell Osteogenesis, Adipogenesis, and Stromal Function. Cells, 2021, 10, 341.	1.8	20
642	Cytokine â€œfine tuningâ€•of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies. Seminars in Immunopathology, 2021, 43, 193-206.	2.8	14
643	Spondyloarthritis and the Human Leukocyte Antigen (HLA)-B*27 Connection. Frontiers in Immunology, 2021, 12, 601518.	2.2	22
644	Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers. Autoimmunity Reviews, 2021, 20, 102760.	2.5	15
645	Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis. Frontiers in Immunology, 2021, 12, 614255.	2.2	28

#	Article	IF	Citations
646	Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies. Journal of Rheumatology, 2021, 48, 1251-1258.	1.0	9
647	Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nature Reviews Rheumatology, 2021, 17, 257-269.	3.5	52
648	Navigating the diverse immune landscapes of psoriatic arthritis. Seminars in Immunopathology, 2021, 43, 279-290.	2.8	7
649	Assessment of enthesopathy in patients with acne vulgaris: A caseâ€controlled trial. Journal of Cosmetic Dermatology, 2021, 20, 3552-3562.	0.8	0
650	Perspectives on the Genetic Associations of Ankylosing Spondylitis. Frontiers in Immunology, 2021, 12, 603726.	2.2	15
651	Tâ€cell memory in tissues. European Journal of Immunology, 2021, 51, 1310-1324.	1.6	14
652	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. Rheumatology, 2021, 60, 5337-5350.	0.9	18
653	Clinical significance of spondyloarthritis-attended enthesites: from pathophysiology to treatment (review). BolÊ¹, Sustavy, PozvonoÄnik, 2021, 11, 17-27.	0.1	0
654	Recent Updates in the Immunopathology of Type 3 Immunity-Mediated Enthesitis. Current Rheumatology Reports, 2021, 23, 31.	2.1	10
655	The arthritis connection to inflammatory bowel disease (IBD): why has it taken so long to understand it?. RMD Open, 2021, 7, e001558.	1.8	23
656	Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes entheseal new bone formation through activation of Hippo signalling in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2021, 80, 891-902.	0.5	24
658	Similarities and Differences Between Juvenile and Adult Spondyloarthropathies. Frontiers in Medicine, 2021, 8, 681621.	1.2	9
659	Innate ILâ€23/Type 17 immune responses mediate the effect of the 17q21 locus on childhood asthma. Clinical and Experimental Allergy, 2021, 51, 892-901.	1.4	3
660	Tissueâ€Resident Memory CD8+ T Cells From Skin Differentiate Psoriatic Arthritis From Psoriasis. Arthritis and Rheumatology, 2021, 73, 1220-1232.	2.9	40
661	IL-23 receptor deficiency results in lower bone mass via indirect regulation of bone formation. Scientific Reports, 2021, 11, 10244.	1.6	4
662	Juvenile Spondyloarthritis: What More Do We Know About HLA-B27, Enthesitis, and New Bone Formation?. Frontiers in Medicine, 2021, 8, 666772.	1.2	8
663	Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. ImmunoTargets and Therapy, 2021, Volume 10, 141-153.	2.7	16
664	Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints. Rheumatology, 2021, 60, iv16-iv27.	0.9	11

#	Article	IF	Citations
665	The impact of genetic background and sex on the phenotype of IL-23 induced murine spondyloarthritis. PLoS ONE, 2021, 16, e0247149.	1.1	8
666	Mediation of Interleukinâ€23 and Tumor Necrosis Factorâ€“Driven Reactive Arthritis by Chlamydiaâ€Infected Macrophages in SKG Mice. Arthritis and Rheumatology, 2021, 73, 1200-1210.	2.9	5
667	Inflammasome Activation in Ankylosing Spondylitis Is Associated With Gut Dysbiosis. Arthritis and Rheumatology, 2021, 73, 1189-1199.	2.9	32
668	Infliximab prevents systemic bone loss and suppresses tendon inflammation in a collagen-induced arthritis rat model. Inflammopharmacology, 2021, 29, 661-672.	1.9	7
669	Interplay of Forces and the Immune Response for Functional Tendon Regeneration. Frontiers in Cell and Developmental Biology, 2021, 9, 657621.	1.8	5
670	Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice. Scientific Reports, 2021, 11, 11923.	1.6	6
671	Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis. Frontiers in Immunology, 2021, 12, 622770.	2.2	21
672	Pathogenesis of psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101694.	1.4	16
673	Biomechanical stress in the context of competitive sports training triggers enthesitis. Arthritis Research and Therapy, 2021, 23, 172.	1.6	8
674	Clinical and molecular significance of genetic loci associated with psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101691.	1.4	5
675	Impact of barrier tissue inflammation and physical activity on joint homeostasis in mice. Rheumatology, 2021, , .	0.9	0
676	Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Annals of the Rheumatic Diseases, 2022, 81, 68-73.	0.5	53
677	IL-23 reshapes kidney resident cell metabolism and promotes local kidney inflammation. Journal of Clinical Investigation, 2021, 131, .	3.9	33
678	Tissue-specific therapy in immune-mediated kidney diseases: new ARGuments for targeting the IL-23/IL-17 axis. Journal of Clinical Investigation, 2021, 131, .	3.9	7
679	Ankylosing spondylitis: an autoimmune or autoinflammatory disease?. Nature Reviews Rheumatology, 2021, 17, 387-404.	3.5	130
680	The Role of the IL-23/IL-17 Axis in Disease Initiation in Spondyloarthritis: Lessons Learned From Animal Models. Frontiers in Immunology, 2021, 12, 618581.	2.2	11
681	Targeting the CCR6/CCL20 Axis in Entheseal and Cutaneous Inflammation. Arthritis and Rheumatology, 2021, 73, 2271-2281.	2.9	12
682	Psoriatic Dactylitis: Current Perspectives and New Insights in Ultrasonography and Magnetic Resonance Imaging. Journal of Clinical Medicine, 2021, 10, 2604.	1.0	14

#	Article	IF	Citations
683	5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivative attenuates lupus nephritis with less effect to thymocyte development. Immunologic Research, 2021, 69, 378-390.	1.3	1
684	Food colorants metabolized by commensal bacteria promote colitis in mice with dysregulated expression of interleukin-23. Cell Metabolism, 2021, 33, 1358-1371.e5.	7.2	49
685	Enthesopathy in spondyloarthritis: the literature review. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 316-325.	0.2	0
686	Secukinumab therapy in reactive arthritis: Report of two cases. Modern Rheumatology Case Reports, 2022, 6, 22-24.	0.3	4
687	Axial spondyloarthritis: emerging drug targets. Expert Opinion on Therapeutic Targets, 2021, 25, 1-12.	1.5	3
688	Recent Updates in Juvenile Spondyloarthritis. Rheumatic Disease Clinics of North America, 2021, 47, 565-583.	0.8	13
689	Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis. Expert Review of Clinical Immunology, 2021, 17, 1073-1081.	1.3	5
690	Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis. Expert Review of Clinical Immunology, 2021, 17, 1059-1071.	1.3	2
691	Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. New England Journal of Medicine, 2021, 385, 628-639.	13.9	156
692	Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies. Frontiers in Immunology, 2021, 12, 770275.	2.2	7
693	Targeting the Interleukin-23/Interleukin-17 Inflammatory Pathway: Successes and Failures in the Treatment of Axial Spondyloarthritis. Frontiers in Immunology, 2021, 12, 715510.	2.2	6
694	Differentiating Psoriatic Arthritis from Osteoarthritis and Rheumatoid Arthritis: A Narrative Review and Guide for Advanced Practice Providers. Rheumatology and Therapy, 2021, 8, 1493-1517.	1.1	13
695	MRI and Sonography of the Knee in Acute Reactive Arthritis. Journal of Clinical Rheumatology, 2021, Publish Ahead of Print, .	0.5	2
696	New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. Journal of Investigative Dermatology, 2021, 141, 2112-2122.e3.	0.3	19
697	Paradoxical Augmentation of Experimental Spondyloarthritis by RORC Inhibition in HLA-B27 Transgenic Rats. Frontiers in Immunology, 2021, 12, 699987.	2.2	3
698	Valve Abnormalities, Risk Factors for Heart Valve Disease and Valve Replacement Surgery in Spondyloarthritis. A Systematic Review of the Literature. Frontiers in Cardiovascular Medicine, 2021, 8, 719523.	1.1	7
699	Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics. Open Access Rheumatology: Research and Reviews, 2021, Volume 13, 293-303.	0.8	2
700	Immune Response to Borrelia: Lessons from Lyme Disease Spirochetes. Current Issues in Molecular Biology, 2022, 42, 145-190.	1.0	19

#	Article	IF	Citations
701	The transition from enthesis physiological responses in health to aberrant responses that underpin spondyloarthritis mechanisms. Current Opinion in Rheumatology, 2021, 33, 64-73.	2.0	9
702	Neutrophil Extracellular Traps and Interleukin 17 in Ankylosing Spondylitis. Mediterranean Journal of Rheumatology, 2021, 32, 182.	0.3	3
703	Discovery of a Series of Pyrazinone RORÎ³ Antagonists and Identification of the Clinical Candidate BI 730357. ACS Medicinal Chemistry Letters, 2021, 12, 143-154.	1.3	12
704	Overview of Axial Spondyloarthritis. , 2014, , 5-16.		2
705	Osteoporosis in Rheumatologic Conditions and Inflammatory Disorders. , 2017, , 225-249.		1
706	Juvenile idiopathische Arthritis. , 2014, , 169-281.		1
707	Spondyloarthritides. , 2020, , 691-701.		1
708	Etiology, pathogenesis, and pathophysiology of ankylosing spondylitis. , 2015, , 951-955.		1
709	Disease modifying drugs for rheumatological diseases: a brief history of everything. Advances in Protein Chemistry and Structural Biology, 2020, 120, 313-348.	1.0	5
710	Double-negative T cells in autoimmune diseases. Current Opinion in Rheumatology, 2021, 33, 163-172.	2.0	34
711	Antibody-dependent and -independent mechanisms of inflammatory arthritis. JCI Insight, 2019, 4, .	2.3	38
712	Tristetraprolin expression by keratinocytes controls local and systemic inflammation. JCI Insight, 2017, 2, .	2.3	42
713	TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis. Journal of Clinical Investigation, 2020, 130, 1863-1878.	3.9	51
714	Efficacy of High Intensity Exercise on Disease Activity and Cardiovascular Risk in Active Axial Spondyloarthritis: A Randomized Controlled Pilot Study. PLoS ONE, 2014, 9, e108688.	1.1	83
715	Gene Expression Profiling in Peripheral Blood Cells and Synovial Membranes of Patients with Psoriatic Arthritis. PLoS ONE, 2015, 10, e0128262.	1.1	62
716	Increased expression of Th17 cytokines and interleukin-22 correlates with disease activity in pristane-induced arthritis in rats. PLoS ONE, 2017, 12, e0188199.	1.1	4
717	A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA-/- and mutant-p53. PLoS ONE, 2018, 13, e0193485.	1.1	8
718	MODERN IDEA ON THE PATHOGENESIS OF SPONDYLOARTHRITIS: MOLECULAR MECHANISMS. Nauchno-Prakticheskaya Revmatologiya, 2015, 53, 299.	0.2	9

#	Article	IF	Citations
719	Psoriatic arthritis: pathogenetic features and innovative therapies. Nauchno-Prakticheskaya Revmatologiya, 2019, 56, 685-691.	0.2	10
720	Aberrant upregulation of CaSR promotes pathological new bone formation in ankylosing spondylitis. EMBO Molecular Medicine, 2020, 12, e12109.	3.3	22
721	Is there a link between IL-23/IL-17 and developmental pathways such as the Wnt and Hedgehog pathway?. Mediterranean Journal of Rheumatology, 2017, 28, 59-61.	0.3	1
722	The Concept and Overview of Spondyloarthritis. Korean Journal of Medicine, 2013, 85, 229.	0.1	3
723	Concomitant Disruption of CD4 and CD8 Genes Facilitates the Development of Double Negative Î±Î² TCR+ Peripheral T Cells That Respond Robustly to Staphylococcal Superantigen. Journal of Immunology, 2017, 198, 4413-4424.	0.4	7
724	MicroRNA-10b Plays a Role in Bone Formation by Suppressing Interleukin-22 in Ankylosing Spondylitis. Journal of Rheumatic Diseases, 2020, 27, 61.	0.4	6
725	Targeting IL-17 in psoriatic arthritis. European Journal of Rheumatology, 2017, 4, 272-277.	1.3	32
726	Association between rs7517847 and rs2201841 polymorphisms in IL-23 receptor gene and risk of ankylosing spondylitis: a meta-analysis. PeerJ, 2015, 3, e910.	0.9	10
727	Complexity of enthesitis and new bone formation in ankylosing spondylitis: current understanding of the immunopathology and therapeutic approaches. Modern Rheumatology, 2022, 32, 484-492.	0.9	11
728	A review of JAKâ€“STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology, 2022, 61, 1783-1794.	0.9	31
729	Inflammatory Foot Involvement in Spondyloarthritis: From Tarsitis to Ankylosing Tarsitis. Frontiers in Medicine, 2021, 8, 730273.	1.2	3
730	Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 2021, 9, 1511.	1.4	40
731	Immunopathophysiology of Juvenile Spondyloarthritis (jSpA): The â€œOut of the Boxâ€•View on Epigenetics, Neuroendocrine Pathways and Role of the Macrophage Migration Inhibitory Factor (MIF). Frontiers in Medicine, 2021, 8, 700982.	1.2	5
732	IL-23 in Health and Disease. , 2014, , 179-198.		1
733	Macrophage in Enthesis: A Likely Contributing Factor to Enthesitis through IL-23 in Ankylosing Spondylitis. Rheumatology (Sunnyvale, Calif), 2014, S4, .	0.3	0
734	Genetics of axial spondyloarthritis. , 2015, , 956-959.		1
735	Interleukin 23. , 2015, , 1-10.		0
736	Enthesopathies. , 2015, , 1014-1020.		0

#	Article	IF	Citations
737	Etiology and pathogenesis of psoriatic arthritis. , 2015, , 998-1007.		0
738	Juvenile-onset spondyloarthritis. , 2015, , 862-867.		0
739	Implication de la voie Th17 dans la physiopathologie des spondyloarthrites. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 1177-1185.	0.0	0
741	Mechanisms of Bone Remodelling in Psoriatic Arthritis. , 2016, , 111-126.		0
742	Innate and Acquired Cellular Immune Responses in Psoriasis and Psoriatic Arthritis. , 2016, , 61-72.		0
743	Interleukin 23. , 2016, , 741-749.		0
744	Ankylosing Spondylitis: A Multi-Factorial Autoimmune Disease. MHC Class I, Antigen Presentation and others to Blame. Autoimmune and Infectious Diseases: Open Access, 2016, 2, .	0.1	0
746	Two Subsets of Large Vessel Vasculitis Characterized by the Absence or Presence of Spondyloarthritis or its Associated Diseases. Open Rheumatology Journal, 2016, 10, 101-108.	0.1	2
747	The Role of IL-17/Th17 Pathway in the Pathogenesis of Autoimmune Inflammatory Diseases. , 2017, , 47-53.		1
748	The Intestinal Microbiome, the Immune System and Spondyloarthropathy. , 2017, , 145-165.		0
749	Isolation and Characterization of Aerobic Gut Microbiome of Psoriatic Arthritic and Psoriasis Patients. SBV Journal of Basic Clinical and Applied Health Science, 2018, 1, 20-24.	0.2	0
751	ENTHESITIS AND PSORIATIC ONYCHOPATHY AS A FACTOR FOR PREDICTION OF PSORIATIC ARTHRITIS IN PSORIASIS. Vestnik Dermatologii I Venerologii, 2018, 94, 38-50.	0.2	2
753	A New Medical Therapy for Axial Spondyloarthritis. Korean Journal of Medicine, 2018, 93, 424-429.	0.1	0
754	Research Progress in Pathophysiological Mechanism of Enthesitis in Spondyloarthritis. Advances in Clinical Medicine, 2019, 09, 1306-1314.	0.0	0
755	Immunotherapy for Spondyloarthritis (SpA). , 2019, , 45-55.		0
756	Reactive Arthritis: Animal Models. , 2019, , 373-379.		0
757	DISTINGUISHING FEATURES OF MUSCULOSKELETAL SYSTEM EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Bulletin of Problems Biology and Medicine, 2019, 4, 89.	0.0	2
758	Psoriatic Arthritis: A Current Vision. , 2019, , 105-105.		0

#	Article	IF	Citations
760	Immunological Basis of Inflammatory Arthritides. , 2020, , 1-36.		1
761	Disease Mechanisms. , 2020, , 209-222.		1
762	Results of direct comparison of the clinical efficacy of ixekizumab and adalimumab: data from the SPIRIT H2H study. Sovremennaya Revmatologiya, 2020, 14, 50-56.	0.1	0
763	The Cellular Composition of the Uveal Immune Environment. Frontiers in Medicine, 2021, 8, 721953.	1.2	8
764	Adaptive Immune-Related Cells and Cytokines in Spondyloarthropathies. , 2022, , 49-82.		0
765	The Prevalence of Cardiac Diseases in a Contemporary Large Cohort of Dutch Elderly Ankylosing Spondylitis Patientsâ€"The CARDAS Study. Journal of Clinical Medicine, 2021, 10, 5069.	1.0	10
766	Innate Immune-Related Cells and Cytokines in Spondyloarthropathies. , 2022, , 25-48.		0
767	IL-22 increases the production of sFRP3 by FLS in inflammatory joint diseases. Brazilian Journal of Medical and Biological Research, 2020, 53, e9880.	0.7	3
769	Applications of tailored polysaccharides in orthopedics. , 2020, , 259-286.		1
770	T Cells in The Regulation of Bone Metabolism. , 2020, , 12-19.		0
771	Inflammatory Arthritis: Ankylosing Spondylitis. , 2020, , 689-696.		0
772	Aortic root diameter is associated with HLA-B27: identifying the patient with ankylosing spondylitis at risk for aortic valve regurgitation. Rheumatology International, 2022, 42, 683-688.	1.5	7
773	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. Journal of Clinical and Aesthetic Dermatology, 2013, 6, S2-S20.	0.1	17
774	American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting. P and T, 2017, 42, 202-204.	1.0	1
775	Bone Wasn't Built in a Day: Destruction and Formation of Bone in the Rheumatic Diseases. Transactions of the American Clinical and Climatological Association, 2017, 128, 24-43.	0.9	8
777	Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis. Nature Communications, 2021, 12, 6540.	5.8	20
778	The Antidiabetic Agent Metformin Inhibits IL-23 Production in Murine Bone-Marrow-Derived Dendritic Cells. Journal of Clinical Medicine, 2021, 10, 5610.	1.0	1
779	Unexpected connections of the IL-23/IL-17 and IL-4/IL-13 cytokine axes in inflammatory arthritis and enthesitis. Seminars in Immunology, 2021, 58, 101520.	2.7	23

#	Article	IF	Citations
780	The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. International Journal of Molecular Sciences, 2021, 22, 12793.	1.8	50
781	Population pharmacokinetics and exposureâ€response modeling analyses of guselkumab in patients with psoriatic arthritis. Clinical and Translational Science, 2022, 15, 749-760.	1.5	6
782	Immunopathogenesis of spondyloarthropathies â€“ Concept of major histocompatibility locus-I-opathy. Indian Journal of Rheumatology, 2021, 16, 422.	0.2	0
783	Expanded IL-22⁺ Group 3 Innate Lymphoid Cells and Role of Oxidized LDL-C in the Pathogenesis of Axial Spondyloarthritis with Dyslipidaemia. Immune Network, 2021, 21, e43.	1.6	7
784	A Potential New Mouse Model of Axial Spondyloarthritis Involving the Complement System. Immune Network, 2021, 21, e45.	1.6	4
785	The effects of PBMCs-derived exosomes of ankylosing spondylitis patients on T cell profiles. Gene Reports, 2022, 26, 101446.	0.4	5
786	Tofacitinib Blocks Entheseal Lymphocyte Activation and Modulates MSC Adipogenesis, but Does Not Directly Affect Chondro- and Osteogenesis. Immuno, 2021, 1, 545-557.	0.6	1
787	Bone Involvement in Patients with Spondyloarthropathies. Calcified Tissue International, 2022, 110, 393-420.	1.5	7
788	The impact of anti-TNF treatment on Wnt signaling, noggin, and cytokine levels in axial spondyloarthritis. Clinical Rheumatology, 2022, 41, 1381-1389.	1.0	4
789	ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies. Annals of Hematology, 2022, 101, 469-484.	0.8	19
790	The Potential Role of Genetics, Environmental Factors, and Gut Dysbiosis in the Aberrant Non-Coding RNA Expression to Mediate Inflammation and Osteoclastogenic/Osteogenic Differentiation in Ankylosing Spondylitis. Frontiers in Cell and Developmental Biology, 2021, 9, 748063.	1.8	6
792	Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review. International Immunopharmacology, 2022, 105, 108517.	1.7	4
793	No Significant Effects of IL-23 on Initiating and Perpetuating the Axial Spondyloarthritis: The Reasons for the Failure of IL-23 Inhibitors. Frontiers in Immunology, 2022, 13, 818413.	2.2	1
794	Increased risks of aortic regurgitation and atrial fibrillation in radiographic axial spondyloarthritis patients: a 10-year nationwide cohort study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210880.	1.2	2
795	The inhibitory effect of tocilizumab on systemic bone loss and tendon inflammation in a juvenile Collagen-Induced arthritis rat model. Connective Tissue Research, 2022, , 1-13.	1.1	1
796	Lifestyle modification and inflammation in people with axial spondyloarthropathyâ€"A scoping review. Musculoskeletal Care, 2022, , .	0.6	3
797	The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights. Pharmaceuticals, 2022, 15, 270.	1.7	10
798	Combined Single Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning. Frontiers in Immunology, 2022, 13, 835760.	2.2	11

#	Article	IF	Citations
799	Nuevas alternativas de tratamiento en espondilitis anquilosante y artritis psoriÃ¡sica. Global Rheumatology, 0, , .	0.0	0
802	Effects of Biological/Targeted Therapies on Bone Mineral Density in Inflammatory Arthritis. International Journal of Molecular Sciences, 2022, 23, 4111.	1.8	5
803	B Cells on the Stage of Inflammation in Juvenile Idiopathic Arthritis: Leading or Supporting Actors in Disease Pathogenesis?. Frontiers in Medicine, 2022, 9, 851532.	1.2	6
804	B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis. International Journal of Molecular Sciences, 2021, 22, 13325.	1.8	17
805	Interleukin-23 receptor expressing Î³Î´ T cells locally promote early atherosclerotic lesion formation and plaque necrosis in mice. Cardiovascular Research, 2022, 118, 2932-2945.	1.8	13
806	Exploring the Diverse Immune and Genetic Landscape of Psoriatic Arthritis. Journal of Clinical Medicine, 2021, 10, 5926.	1.0	2
807	Prevalence and Risk for Bundle Branch Block, Atrioventricular Block and Pacemaker Implantation in Spondyloarthritis. A Systematic Review of the Literature. Frontiers in Medicine, 2022, 9, 851483.	1.2	0
808	Peripheral Î³Î´ T Cells Regulate Neutrophil Expansion and Recruitment in Experimental Psoriatic Arthritis. Arthritis and Rheumatology, 2022, 74, 1524-1534.	2.9	17
809	Interleukin-17 Links Inflammatory Cross-Talks Between Comorbid Psoriasis and Atherosclerosis. Frontiers in Immunology, 2022, 13, 835671.	2.2	7
834	Psoriatic arthritis from a mechanistic perspective. Nature Reviews Rheumatology, 2022, 18, 311-325.	3.5	49
836	A Mechanistic Insight into the Pathogenic Role of Interleukin 17A in Systemic Autoimmune Diseases. Mediators of Inflammation, 2022, 2022, 1-14.	1.4	3
837	Enthesitis-assoziierte Arthritis bei Kindern und Jugendlichen. Springer Reference Medizin, 2022, , 393-402.	0.0	1
838	TNF inhibitors have a protective role in the risk of dementia in patients with ankylosing spondylitis: Results from a nationwide study. Pharmacological Research, 2022, 182, 106325.	3.1	12
839	Mechanisms of joint destruction in rheumatoid arthritis â€" immune cellâ€"fibroblastâ€"bone interactions. Nature Reviews Rheumatology, 2022, 18, 415-429.	3.5	124
840	Molecular and cellular regulation of psoriatic inflammation. Clinical Science, 2022, 136, 935-952.	1.8	1
841	Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?. Expert Opinion on Biological Therapy, 2022, 22, 1439-1441.	1.4	1
842	DKK-1 Is Underexpressed in Mesenchymal Stem Cells from Patients with Ankylosing Spondylitis and Further Downregulated by IL-17. International Journal of Molecular Sciences, 2022, 23, 6660.	1.8	11
843	IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?. Expert Opinion on Biological Therapy, 2022, 22, 843-853.	1.4	4

#	Article	IF	Citations
844	The Role of Interleukin-23 Inhibition in the Treatment of Psoriatic Arthritis. , 2022, 1, 18.		0
845	Elevated Th17 cell proportion, related cytokines and mRNA expression level in patients with hypertension-mediated organ damage: a case control study. BMC Cardiovascular Disorders, 2022, 22, .	0.7	3
848	Characterization of mucosalâ€associated invariant T cells in blood of patients with axial spondyloarthritis and in axial entheses of healthy controls: comment on the article by Rosine et al. Arthritis and Rheumatology, 2022, 74, 2045-2046.	2.9	0
849	The gut-enthesis axis and the pathogenesis of Spondyloarthritis. Seminars in Immunology, 2021, 58, 101607.	2.7	7
850	Deep Insight into the Role of MIF in Spondyloarthritis. Current Rheumatology Reports, 2022, 24, 269-278.	2.1	2
851	Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms. Current Rheumatology Reports, 2022, 24, 310-320.	2.1	9
852	Emerging story of gut dysbiosis in spondyloarthropathy: From gastrointestinal inflammation to spondyloarthritis. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	4
853	The identification of association between ultrasonographic enthesitis and the ASAS Health Index in patients with axial spondyloarthritis. Rheumatology International, 0, , .	1.5	0
854	Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology. Mediterranean Journal of Rheumatology, 2022, 33, 126.	0.3	4
855	The role of ILâ€23 and the use of ILâ€23 inhibitors in psoriatic arthritis. Musculoskeletal Care, 2022, 20, .	0.6	13
857	Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis. Rheumatology and Therapy, 2022, 9, 1451-1464.	1.1	2
858	Spondyloarthritis: How far are we from precision medicine?. Frontiers in Medicine, 0, 9, .	1.2	1
859	Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy. Nature Communications, 2022, 13, .	5.8	38
860	Regulation and Reconstruction of Cell Phenotype Gradients Along the Tendonâ€Bone Interface. Advanced Functional Materials, 0, , 2210275.	7.8	5
861	Advanced genomics and clinical phenotypes in psoriatic arthritis. Seminars in Immunology, 2021, 58, 101665.	2.7	1
862	Postoperative analgesic effect of dexmedetomidine combined with TPVB applied to open gastrectomy for gastric cancer. Immunopharmacology and Immunotoxicology, 2023, 45, 234-239.	1.1	1
863	Joint together: The etiology and pathogenesis of ankylosing spondylitis. Frontiers in Immunology, 0, 13, .	2.2	16
864	Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis. International Journal of Molecular Sciences, 2022, 23, 13913.	1.8	8

#	Article	IF	Citations
865	Peripheral spondyloarthritis and psoriatic arthritissine psoriase: are we dealing with semantics or clinically meaningful differences?. RMD Open, 2022, 8, e002592.	1.8	2
866	An overview of psoriatic arthritis including clinical manifestations, assessment, diagnostic criteria, investigations, drug management and GRAPPA guidelines. Musculoskeletal Care, 2022, 20, .	0.6	0
867	Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open, 2022, 12, e063650.	0.8	10
868	Whatâ€™s new and whatâ€™s next for biological and targeted synthetic treatments in psoriatic arthritis?. Expert Opinion on Biological Therapy, 2022, 22, 1545-1559.	1.4	3
869	Spondyloarthritides: Theories and beyond. Frontiers in Pediatrics, 0, 10, .	0.9	0
870	Bibliometric analysis of publications on enthesitis in spondyloarthritis in 2012â€“2021 based on web of science core collection databases. Rheumatology International, 2023, 43, 173-182.	1.5	4
871	A conserved population of MHC II-restricted, innate-like, commensal-reactive T cells in the gut of humans and mice. Nature Communications, 2022, 13, .	5.8	6
872	Piezo1-mediated mechanotransduction promotes entheseal pathological new bone formation in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2023, 82, 533-545.	0.5	9
873	Tissue-resident immune cells in the pathogenesis of multiple sclerosis. Inflammation Research, 2023, 72, 363-372.	1.6	0
874	Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?. Current Rheumatology Reports, 2023, 25, 56-67.	2.1	3
875	Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy. Nature Reviews Rheumatology, 2023, 19, 153-165.	3.5	7
876	Effect of T cells on bone. Bone, 2023, 168, 116675.	1.4	3
877	Evaluation of the measurement of tendon and ligament thicknesses and the presence of enthesitis in lower extremities in female patients with acne vulgaris: a randomized controlled trial. Journal of Medicine and Palliative Care:, 2022, 3, 354-358.	0.0	0
878	RORÎ³t inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating Î³Î´-T cells. Rheumatology, 0, , .	0.9	9
879	Rheumatic diseases: The microbiota-immunity axis in development and treatment. , 2023, , 83-111.		0
881	Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naÃ¯ve patients with active psoriatic arthritis. RMD Open, 2023, 9, e002789.	1.8	4
882	Psoriatic Arthritis: Pathogenesis and Targeted Therapies. International Journal of Molecular Sciences, 2023, 24, 4901.	1.8	15
883	Rotating Magnetic Field Mitigates Ankylosing Spondylitis Targeting Osteocytes and Chondrocytes via Ameliorating Immune Dysfunctions. Cells, 2023, 12, 972.	1.8	2

#	Article	IF	Citations
884	Targeted Therapies in Psoriatic Arthritisâ€"An Update. International Journal of Molecular Sciences, 2023, 24, 6384.	1.8	5
885	Uncovering the Underworld of Axial Spondyloarthritis. International Journal of Molecular Sciences, 2023, 24, 6463.	1.8	6
886	The role of Î³Î´ T cells in the immunopathogenesis of inflammatory diseases: From basic biology to therapeutic targeting. Journal of Leukocyte Biology, 0, , .	1.5	2
894	The bone marrow side of axial spondyloarthritis. Nature Reviews Rheumatology, 2023, 19, 519-532.	3.5	6